



IN THE DISTRICT COURT OF CLEVELAND COUNTY

STATE OF OKLAHOMA  
CLEVELAND COUNTY  
FILED  
FEB 28 2019

STATE OF OKLAHOMA, MIKE HUNTER, ATTORNEY GENERAL, OKLAHOMA,

Case No. CJ-2017-816

Plaintiff,

v.

PURDUE PHARMA L.P., et al

Defendants.

In the office of the Honorable  
Court Clerk MARILYN WILLIAMS

Thad Balkman

TO BE HEARD BY  
William C. Hetherington  
Special Discovery Master

**DEFENDANTS' EMERGENCY MOTION TO STAY EXPERT DEADLINES PENDING A RULING ON CONCURRENT MOTION FOR CONTINUANCE**

Defendants respectfully request on an emergency basis that the Court stay the parties' expert deadlines to preserve the status quo while the Court rules on Defendants' motion for continuance, which is being filed concurrently. (See Exhibit A.)


As shown in that motion, just last week, the State *nearly doubled* the volume of all its prior document productions – with a last-minute dump of *1,596,369* pages of documents, which is so large that it took several days to download and process. And more are coming. For instance, within the last few days alone, the State has produced more than 8,500 pages of other documents – not including other document productions that continue to be rolled out by the State as of the time of this writing. This belated tidal wave of documents comes despite this Court's prior orders compelling the State to produce its documents long ago. Among other things, it is contrary to the Court's January 17, 2019 order compelling the State "to *complete* the required discovery and production on or before February 5, 2019" (Jan. 17, 2019 Hr'g Order at 7 (emphasis added).) It is also contrary to the Court's frequent directives to produce custodial file documents before depositions – many of which have already occurred. The prejudice to Defendants from the State's conduct is substantial, as shown in the motion for a continuance.

Emergency relief is necessary because the deadline for Defendants to issue expert disclosures is tomorrow, which is just six working days from when the State dumped more than 1.59 million pages of its documents. The State's actions deprived Defendants of any fair opportunity for its counsel or its experts to consider 1.59 million pages of the State's document production before making expert disclosures and deprived Defendants of using the State's documents to prepare for both fact and expert depositions.

While the Court rules on Defendants' motion for a continuance, the Court should prevent further prejudice to Defendants by suspending the March 1, 2019 deadline to make expert disclosures and the April 1, 2019 deadline to depose Plaintiffs' experts. These dates can then be reset upon ruling on the motion for a continuance to address the prejudice to Defendants from the State's conduct.

Date: February 28, 2019

Respectfully submitted,



Sanford C. Coats, OBA No. 18268  
Joshua D. Burns, OBA No. 32967  
CROWE & DUNLEVY, P.C.  
Braniff Building  
324 N. Robinson Ave., Ste. 100  
Oklahoma City, OK 73102  
Tel: (405) 235-7700  
Fax: (405) 272-5269  
sandy.coats@crowedunlevy.com  
joshua.burns@crowedunlevy.com

Of Counsel:

Sheila Birnbaum  
Mark S. Cheffo  
Hayden A. Coleman  
Paul A. LaFata  
Jonathan S. Tam  
DECHERT, LLP  
Three Bryant Park

1095 Avenue of the Americas  
New York, New York 10036  
Tel: (212) 698-3500  
Fax: (212) 698-3599  
sheila.birnbaum@dechert.com  
mark.cheffo@dechert.com  
hayden.coleman@dechert.com  
paul.lafata@dechert.com  
jonathan.tam@dechert.com

Eric Wolf Pinker  
John Thomas Cox III  
Lynn Pinker Cox & Hurst, LLP  
2100 Ross Avenue, Suite 2700  
Dallas, TX 75201  
epinker@lynnllp.com  
tcox@lynnllp.com


*Counsel for Purdue Pharma L.P.,  
Purdue Pharma Inc., and The Purdue  
Frederick Company Inc.*

**CERTIFICATE OF SERVICE**

I hereby certify that on February 28, 2019, I caused a true and correct copy of the following:

**DEFENDANTS' EMERGENCY MOTION TO STAY EXPERT DEADLINES PENDING  
A RULING ON CONCURRENT MOTION FOR CONTINUANCE**

to be served via email upon the counsel of record listed on the attached Service List.

A handwritten signature in black ink, consisting of several loops and a long horizontal stroke at the end, positioned above a solid horizontal line.

## SERVICE LIST

### WHITTEN BURRAGE

Michael Burrage  
Reggie Whitten  
512 N. Broadway Avenue, Suite 300  
Oklahoma City, OK 73102  
mburrage@whittenburrage.com  
rwhitten@whittenburrage.com

*Counsel for Plaintiff the State of  
Oklahoma*

### OKLAHOMA OFFICE OF THE ATTORNEY GENERAL

Mike Hunter  
Abby Dillsaver  
Ethan A. Shaner  
313 NE 21st St  
Oklahoma City, OK 73105  
abby.dillsaver@oag.ok.gov  
ethan.shaner@oag.ok.gov

*Counsel for Plaintiff the State of Oklahoma*

### NIX, PATTERSON & ROACH, LLP

Bradley E. Beckworth  
Jeffrey J. Angelovich  
Lloyd "Trey" Nolan Duck, III  
Andrew Pate  
Lisa Baldwin  
Nathan B. Hall  
512 N. Broadway Ave., Suite 200  
Oklahoma City, OK 73102  
bbeckworth@nixlaw.com  
jangelovich@npraustin.com  
tduck@nixlaw.com  
dpate@nixlaw.com  
lbaldwin@nixlaw.com  
nhall@nixlaw.com

*Counsel for Plaintiff the State of Oklahoma*

### GLENN COFFEE & ASSOCIATES, PLLC

Glenn Coffee  
915 N. Robinson Ave.  
Oklahoma City, OK 73102  
gcoffee@glenncoffee.com

*Counsel for Plaintiff the State of Oklahoma*

### ODOM, SPARKS & JONES PLLC

Benjamin H. Odom  
John H. Sparks  
Michael W. Ridgeway  
David L. Kinney  
HiPoint Office Building  
2500 McGee Drive Ste. 140  
Oklahoma City, OK 73072  
odomb@odomsparks.com  
sparksj@odomsparks.com  
ridgewaym@odomsparks.com  
kinneyd@odomsparks.com  
*Counsel for Defendants Janssen  
Pharmaceuticals, Inc., Johnson & Johnson,  
Janssen Pharmaceutica, Inc. n/k/a Janssen  
Pharmaceuticals, Inc., and Ortho-McNeil-*

### FOLIART, HUFF, OTTAWAY & BOTTOM

Larry D. Ottaway  
Amy Sherry Fischer  
201 Robert S. Kerr Avenue, 12th Floor  
Oklahoma City, OK 73102  
larryottaway@oklahomacounsel.com  
amyfischer@oklahomacounsel.com  
*Attorneys for Defendants Johnson & Johnson,  
Janssen Pharmaceuticals, Inc., Janssen  
Pharmaceutica, Inc. n/k/a Janssen  
Pharmaceuticals, Inc., and Ortho-McNeil-  
Janssen Pharmaceuticals, Inc. n/k/a Janssen  
Pharmaceuticals, Inc and Ortho-McNeil-  
Janssen Pharmaceuticals, Inc. n/k/a Janssen  
Pharmaceuticals, Inc.*

*Janssen Pharmaceuticals, Inc. n/k/a/ Janssen Pharmaceuticals, Inc and Ortho-McNeil-Janssen Pharmaceuticals, Inc. n/k/a/ Janssen Pharmaceuticals, Inc.*

**O'MELVENY & MYERS LLP**

Stephen D. Brody  
David K. Roberts  
1625 Eye Street NW  
Washington, DC 20006  
sbrody@omm.com  
droberts2@omm.com

*Counsel for Defendants Janssen Pharmaceuticals, Inc., Johnson & Johnson, Janssen Pharmaceutica, Inc. n/k/a/ Janssen Pharmaceuticals, Inc., and Ortho-McNeil-Janssen Pharmaceuticals, Inc. n/k/a/ Janssen Pharmaceuticals, Inc and Ortho-McNeil-Janssen Pharmaceuticals, Inc. n/k/a/ Janssen Pharmaceuticals, Inc.*

**DECHERT, LLP**

Sheila Birnbaum  
Mark S. Cheffo  
Hayden A. Coleman  
Paul A. LaFata  
Jonathan S. Tam  
Erik Snapp  
Three Bryant Park  
1095 Avenue of the Americas  
New York, New York 10036  
sheila.birnbaum@dechert.com  
mark.cheffo@dechert.com  
hayden.coleman@dechert.com  
paul.lafata@dechert.com  
jonathan.tam@dechert.com  
erik.snapp@dechert.com

*Counsel for Purdue Pharma L.P., Purdue Pharma Inc. and The Purdue Frederick Company Inc.*

**O'MELVENY & MYERS LLP**

Charles C. Lifland  
Jennifer D. Cardelús  
400 S. Hope Street  
Los Angeles, CA 90071  
clifland@omm.com  
jcardelus@omm.com

*Counsel for Defendants Janssen Pharmaceuticals, Inc., Johnson & Johnson, Janssen Pharmaceutica, Inc. n/k/a/ Janssen Pharmaceuticals, Inc., and Ortho-McNeil-Janssen Pharmaceuticals, Inc. n/k/a/ Janssen Pharmaceuticals, Inc.*

**LYNN PINKER COX & HURST, LLP**

Eric Wolf Pinker  
John Thomas Cox III  
Lynn Pinker Cox & Hurst, LLP  
2100 Ross Avenue, Suite 2700  
Dallas, TX 75201  
epinker@lynnllp.com  
tcox@lynnllp.com

*Counsel for Purdue Pharma L.P., Purdue Pharma Inc. and The Purdue Frederick Company Inc.*

GABLEGOTWALS

Robert G. McCampbell

Nicholas V. Merkley

Ashley E. Quinn

One Leadership Square, 15th Fl.

211 North Robinson

Oklahoma City, OK 73102-7255

RMcCampbell@Gablelaw.com

NMerkley@Gablelaw.com

AQuinn@Gablelaw.com

*Attorneys for Defendants Cephalon, Inc., Teva*

*Pharmaceuticals USA, Inc., Watson*

*Laboratories, Inc., Actavis LLC, and Actavis*

*Pharma, Inc. f/k/a/ Watson Pharma, Inc.*

MORGAN, LEWIS & BOCKIUS LLP

Steven A. Reed

Harvey Bartle IV

Rebecca Hillyer

Lindsey T. Mills

1701 Market Street

Philadelphia, PA 19103-2921

steven.reed@morganlewis.com

harvey.bartle@morganlewis.com

rebeccahillyer@morganlewis.com

lindsey.mills@morganlewis.com

*Attorneys for Defendants Cephalon, Inc., Teva*

*Pharmaceuticals USA, Inc., Watson*

*Laboratories, Inc., Actavis LLC, and Actavis*

*Pharma, Inc. f/k/a/ Watson Pharma, Inc.*

MORGAN, LEWIS & BOCKIUS LLP

Brian M. Ercole

200 S. Biscayne Blvd., Suite 5300

Miami, FL 33131

[brian.ercole@morganlewis.com](mailto:brian.ercole@morganlewis.com)

*Attorneys for Defendants Cephalon, Inc., Teva*

*Pharmaceuticals USA, Inc., Watson*

*Laboratories, Inc., Actavis LLC, and Actavis*

*Pharma, Inc. f/k/a/ Watson Pharma, Inc.*

# **EXHIBIT A**





Now, however, that opportunity is lost under the Court's current schedule. Fact discovery will close March 15. Most of the State's witnesses have already been deposed, and the other depositions will happen without the benefit of meaningful review of these documents. At the same time, expert discovery is starting. Tomorrow, the Defendants' experts have to produce reports without the benefit of these newly produced documents, and then within days sit for depositions where they could be cross-examined with those same documents. Defendants must seek emergency relief from the deadline tomorrow as a result.

Maybe this massive 11<sup>th</sup>-hour production was the result of an oversight of monumental proportions, which begs the questions of whether the State and its private attorneys did their diligence before bringing this lawsuit, and why the State failed to find these documents sooner, despite repeated requests. Or maybe this was an intentional strategy of the State's private attorneys to protect their witnesses from difficult questions that would undermine the State's claims, or to play "gotcha" with Defendants' experts. Regardless, the prejudice to Defendants is plain, and it threatens the fairness and ultimate result of any trial.

Last week's avalanche is undoubtedly not the last of the State's last-minute discovery surprises. The State has been stonewalling discovery for much of the last year, forcing Defendants to file motion after motion, resulting in several orders to compel the State to produce discovery—orders that the State ignored. For instance, the Special Discovery Master's January 17, 2019 order compelled the State "to *complete* the required discovery and production on or before February 5, 2019" for a host of long-outstanding discovery requests. (Jan. 17, 2019 Hr'g Order at 7 (emphasis added).) It still has not happened: Among other examples, on February 22, 2019, Purdue catalogued in detail many of the State's outstanding discovery deficiencies, ranging from missing custodial files for prospective witnesses in many State agencies to defined

document categories – discovery sought many months ago in letters, motion practice, and Discovery Master Orders. (Feb. 22, 2019 Ltr. from E. Ryan to D. Pate (Ex. A).) The State did not respond.

The State believes it should recover billions of dollars for prescriptions that the Healthcare Authority authorized before they were dispensed, and that the Authority decided were medically necessary before they were reimbursed. Yet the State *still* has not produced key custodial files for Healthcare Authority employees who would be subject to deposition, several of whom have been requested since last October. (*Id.* at 2-3, 5-8.) Other documents categories from the Healthcare Authority are also still missing. (*Id.* at 9-10.) Do those missing documents show that the OHCA knowingly approved these prescriptions as medically necessary, which bars the State from now claiming they were improper? Or do the missing documents show that the OHCA violated federal law and knowingly approved as “medically necessary” prescriptions that were improper? Defendants do not know, because we just got these documents and need time to review them and then pose these questions to the State’s witnesses.

Similarly, only now are Defendants finally getting access to the State’s records that purportedly serve as the basis for the original and revised opinions of the State’s experts. How will the defense experts prepare responses that take into account this newly produced evidence, and prepare for their own depositions?

Finally, due to the State’s prior failure to produce timely expert reports that comply with the Oklahoma Rules and provide the basis for the experts’ opinions, Defendants are now faced with a compressed schedule for the parties to brief and this Court to consider the dispositive motions and *Daubert* challenges still to come. Under the current schedule, for example, Defendants will have to brief the challenges to the admissibility of the State’s experts before

their depositions are complete. Dispositive motions are due a day before the scheduled *Daubert* hearing. By the time the motions are fully briefed and the *Daubert* hearings concluded, the Court will have two weeks to consider and decide these critical and threshold legal issues, which may eliminate or narrow the issues and evidence to be presented at any trial.

These are real concerns that go to the heart of the fairness of this proceeding. A rush to trial has always been the favored strategy of the State's private attorneys, who have weaponized the discovery process and the expedited schedule, perhaps to pressure Defendants, and perhaps because they do not want evidence that would damage their case from coming to light. Either way, this is not even-handed justice.

The State will inevitably—and loudly—accuse Defendants of delay and cite their predictions about an eventual motion for continuance. Make no mistake: this motion is the result of the State's gamesmanship and discovery abuses. The State chose not to produce 1.6 million pages of responsive documents in response to timely discovery requests and Court orders from long ago. The State chose to make that production without explanation—literally days before the end of the discovery period—and without notice, despite numerous conferences and hearings, and near-daily efforts by Defendants to communicate about discovery. The State chose to produce those documents after the depositions of most State witnesses. Put simply, the State created the discovery problems that now require a continuance

Defendants therefore respectfully request a 100-day continuance of all pretrial dates other than the close of fact discovery, with the trial rescheduled to begin September 16. This is the minimum time required to further the requirements of fairness and due process, and it would still leave this as the first opioid case scheduled for trial. During this extended period, Defendants

should be afforded the opportunity to re-open necessary discovery against the State to the full extent warranted by the State's delinquent discovery responses.

### ARGUMENT

Oklahoma law permits this Court to "continue [an] action at any stage of the proceedings upon terms as may be just." Okla. Stat. Ann. tit. 12, § 667. This statute aligns with the Court's inherent power to control its docket within sound discretion. *Boston v. Buchanan*, 2003 OK 114, 89 P.3d 1034, 1044 (citing *Hambright v. City of Cleveland*, 1960 OK 184, 360 P.2d 493, 496, *Kennedy v. District Court*, 121 Mont. 320, 194 P.2d 256, 264, 2 A.L.R.2d 1050 (1948)).

The mere desire to try a case fast is not an acceptable basis to deny a continuance that is necessary to protect the rights of the parties. For decades, the Supreme Court of Oklahoma has embraced this bedrock principle: "[W]hen a trial is forced with such dispatch as to result in depriving an interested party of reasonable opportunity to prepare for trial, and secure witnesses; and the whole circumstances are such as to convince that there was an abuse of judicial discretion, it is the duty of this court to reverse." *State v. Duerkson*, 1943 OK 6, 191 Okla. 670, 132 P.2d 649, 650. This is particularly true when the amount in controversy is "substantial and the case is quite important to all who are or may be interested." *Id.* The "chief test" when considering a continuance request is "whether the grant or denial of the motion operates in the furtherance of justice." *Id.*

The Supreme Court has also overruled a trial court's refusal to grant a continuance where a plaintiff's selective refusal to waive the doctor-patient privilege until trial allowed "plaintiff to present testimony of some doctors selected by him and close the mouth of another doctor he had consulted, who might contradict him." *Herbert v. Chicago, R.I. & P. R. Co.*, 1975 OK 160, 544 P.2d 898, 901. Indeed, the denial of a continuance will violate due process when it denies the

defendant the opportunity to “fully develop the facts” that are needed for a “full and complete hearing.” *Cent. State Cmty. Serv. v. Anderson*, 2012 OK CIV APP 110, ¶ 11, 292 P.3d 36, 39. The State’s massive, last minute productions have significantly prejudiced Defendants at a critical pretrial juncture, fewer than 90 days from the current start of trial –just three weeks before the close of fact discovery– and notably beyond the time when Defendants could serve any follow-up discovery implicated by the State’s productions, given the 30 days provided for responses. Defendants have no ability to review all of this material within the remaining discovery period, and certainly not by tomorrow, when defendants must disclose their experts’ opinions. Defendants have already lost the ability to use this evidence with most of the State’s witnesses. Within a matter of a few weeks, Defendants will also lose the opportunity to cross-examine the State’s experts with the very evidence upon which they relied—much of which is still being produced long after it was requested by Defendants, required by the Oklahoma Rules, and ordered by the Court, and some of which is still being withheld for no good reason.

For example, even after repeated motion practice and discovery orders, the State still refuses to produce key documents from the Oklahoma Employee Group Insurance Division (EGID). This is the agency that continues to list OxyContin as “clinically appropriate” and a “*preferred* brand-name medicine[.]” (HealthChoice Std. Medication List at 1 (Jan. 2019) (Ex. B) (emphasis added).) Yet EGID’s Chief Medical Officer testified that the State’s lawyers never asked him for documents, (Lawler Dep. (Ex. C) at 144:5-11), despite Defendants’ months-long requests for his custodial file. Even worse, the State’s lawyers never told the Chief Medical Officer to preserve documents until just two or three months ago. (*Id.* at 145:15-20.) This

testimony reveals that the State has not been attending to even basic discovery duties, and this failure may have led to spoliation of evidence.<sup>1</sup>

As another example, when the State de-identified its claims data to remove patient and physician information, it superimposed anonymized codes in the complex data productions that do not correspond to one another (as the patient and physician information would). This resulted in another emergency motion by Defendants. (Defs' Emergency Mot. to Compel, filed Feb. 12, 2019.) On February 18, 2019, Special Master Hetherington ordered the State to correct these and other defects in their database productions, but not until March 1. (Feb. 18, 2019 Hr'g Order at 4.) That is just two weeks before the close of discovery, the day expert disclosures are due, and almost 14 months after Defendants requested the data.

Also consider Defendants' expert disclosures, which are due tomorrow. The experts have no chance to review the 1.6 million pages of documents just produced, so any disclosure will not be able to take that information into account. The experts also will not have the advantage of the numerous documents the State continues to withhold, even though Defendants requested them repeatedly, and the Court ordered the State to produce them. Because of this, the defense experts may also be open to unfair criticism from the State's lawyers.

The prejudice does not end with the close of expert discovery. Due to the State's failure to comply with the expert disclosure deadline, the Court had to substantially shift the timing for expert disclosures and extend the time for expert depositions. At the same time, the trial date remains unchanged, thereby compressing and overlapping the parties' and the Court's work on

---

<sup>1</sup> In the interest of full disclosure, Purdue also notes that it recently learned a (former) discovery vendor did not properly process approximately less than 1.0% of Purdue's documents, totaling about 51,000 documents, which led to their production in some instances without track changes or comment bubbles. In the coming days, Purdue is remedying this technical glitch with a corrected production.

*Daubert* and summary judgment issues Defendants will have to brief *Daubert* before the end of expert discovery and will simultaneously have to brief dispositive motions, which are due just one day after the *Daubert* hearing. The *Daubert* issues will be far from simple, for the State's unqualified experts use unprecedented theories to claim billions of dollars in state entitlements for routine state expenditures never before claimed by the State. By the time dispositive motions are fully briefed, the Court will have only two weeks to consider them. Perhaps by then it will be apparent to the Court that the State has no case at all. But at a minimum, the dispositive and other pretrial motions surely will narrow the evidence and issues appropriate for trial. In the interest of efficiency, fairness, and to ensure an adequate appellate record, the Court should leave itself time to give these motions the consideration they are due.


### CONCLUSION

This is an important case for all parties and for Oklahomans. So it is also important to do this right—to allow Defendants the opportunity to prepare a defense that accounts for the massive amounts of information just produced, and the additional information sure to come in the next two weeks. A continuance serves the interests of justice and results in a relatively short delay. The alternative is a fundamentally unfair pretrial process that is destined to end in an equally unfair trial. Defendants respectfully submit that this Court should grant the request for a continuance and extend all deadlines apart from the close of fact discovery by 100 days.



Date: February 28, 2019

Respectfully submitted,



Sanford C. Coats, OBA No. 18268  
Joshua D. Burns, OBA No. 32967  
CROWE & DUNLEVY, P.C.  
Braniff Building  
324 N. Robinson Ave., Ste. 100  
Oklahoma City, OK 73102  
Tel: (405) 235-7700  
Fax: (405) 272-5269  
sandy.coats@crowedunlevy.com  
joshua.burns@crowedunlevy.com

Of Counsel:

Sheila Birnbaum  
Mark S. Cheffo  
Hayden A. Coleman  
Paul A. LaFata  
Jonathan S. Tam  
DECHERT, LLP  
Three Bryant Park  
1095 Avenue of the Americas  
New York, New York 10036  
Tel: (212) 698-3500  
Fax: (212) 698-3599  
sheila.birnbaum@dechert.com  
mark.cheffo@dechert.com  
hayden.coleman@dechert.com  
paul.lafata@dechert.com  
jonathan.tam@dechert.com

Eric Wolf Pinker  
John Thomas Cox III  
Lynn Pinker Cox & Hurst, LLP  
2100 Ross Avenue, Suite 2700  
Dallas, TX 75201  
epinker@lynnllp.com  
tcox@lynnllp.com

*Counsel for Purdue Pharma L.P.,  
Purdue Pharma Inc., and The Purdue  
Frederick Company Inc.*

**CERTIFICATE OF SERVICE**

I hereby certify that on February 28, 2019, I caused a true and correct copy of the following:

**DEFENDANTS' MOTION FOR A CONTINUANCE**

to be served via email upon the counsel of record listed on the attached Service List.

A handwritten signature in black ink, consisting of a series of loops and a long horizontal stroke at the end, positioned above a solid horizontal line.

## SERVICE LIST

### WHITTEN BURRAGE

Michael Burrage

Reggie Whitten

512 N. Broadway Avenue, Suite 300

Oklahoma City, OK 73102

mburrage@whittenburrage.com

rwhitten@whittenburrage.com

*Counsel for Plaintiff the State of*

*Oklahoma*

### OKLAHOMA OFFICE OF THE ATTORNEY

GENERAL

Mike Hunter

Abby Dillsaver

Ethan A. Shaner

313 NE 21st St

Oklahoma City, OK 73105

abby.dillsaver@oag.ok.gov

ethan.shaner@oag.ok.gov

*Counsel for Plaintiff the State of Oklahoma*

### NIX, PATTERSON & ROACH, LLP

Bradley E. Beckworth

Jeffrey J. Angelovich

Lloyd "Trey" Nolan Duck, III

Andrew Pate

Lisa Baldwin

Nathan B. Hall

512 N. Broadway Ave., Suite 200

Oklahoma City, OK 73102

bbeckworth@nixlaw.com

jangelovich@npraustin.com

tduck@nixlaw.com

dpate@nixlaw.com

lbaldwin@nixlaw.com

nhall@nixlaw.com

*Counsel for Plaintiff the State of Oklahoma*

### GLENN COFFEE & ASSOCIATES, PLLC

Glenn Coffee

915 N. Robinson Ave.

Oklahoma City, OK 73102

gcoffee@glenncoffee.com

*Counsel for Plaintiff the State of Oklahoma*

### ODOM, SPARKS & JONES PLLC

Benjamin H. Odom

John H. Sparks

Michael W. Ridgeway

David L. Kinney

HiPoint Office Building

2500 McGee Drive Ste. 140

Oklahoma City, OK 73072

odomb@odomsparks.com

sparksj@odomsparks.com

ridgewaym@odomsparks.com

kinneyd@odomsparks.com

*Counsel for Defendants Janssen*

*Pharmaceuticals, Inc., Johnson & Johnson,*

*Janssen Pharmaceutica, Inc. n/k/a/ Janssen*

*Pharmaceuticals, Inc., and Ortho-McNeil-*

### FOLIART, HUFF, OTTAWAY & BOTTOM

Larry D. Ottaway

Amy Sherry Fischer

201 Robert S. Kerr Avenue, 12th Floor

Oklahoma City, OK 73102

larryottaway@oklahomacounsel.com

amyfischer@oklahomacounsel.com

*Attorneys for Defendants Johnson & Johnson,*

*Janssen Pharmaceutica, Inc., Janssen*

*Pharmaceutica, Inc. n/k/a Janssen*

*Pharmaceuticals, Inc., and Ortho-McNeil-*

*Janssen Pharmaceutica, Inc. n/k/a/ Janssen*

*Pharmaceuticals, Inc and Ortho-McNeil-*

*Janssen Pharmaceutica, Inc. n/k/a/ Janssen*

*Pharmaceuticals, Inc.*

*Janssen Pharmaceuticals, Inc. n/k/a/ Janssen Pharmaceuticals, Inc and Ortho-McNeil-Janssen Pharmaceuticals, Inc. n/k/a/ Janssen Pharmaceuticals, Inc.*

O'MELVENY & MYERS LLP

Stephen D. Brody  
David K. Roberts  
1625 Eye Street NW  
Washington, DC 20006  
sbrody@omm.com  
droberts2@omm.com

*Counsel for Defendants Janssen Pharmaceuticals, Inc., Johnson & Johnson, Janssen Pharmaceutica, Inc. n/k/a/ Janssen Pharmaceuticals, Inc., and Ortho-McNeil-Janssen Pharmaceuticals, Inc. n/k/a/ Janssen Pharmaceuticals, Inc and Ortho-McNeil-Janssen Pharmaceuticals, Inc. n/k/a/ Janssen Pharmaceuticals, Inc.*

O'MELVENY & MYERS LLP

Charles C. Lifland  
Jennifer D. Cardelús  
400 S. Hope Street  
Los Angeles, CA 90071  
clifland@omm.com  
jcardelus@omm.com

*Counsel for Defendants Janssen Pharmaceuticals, Inc., Johnson & Johnson, Janssen Pharmaceutica, Inc. n/k/a/ Janssen Pharmaceuticals, Inc., and Ortho-McNeil-Janssen Pharmaceuticals, Inc. n/k/a/ Janssen Pharmaceuticals, Inc.*

DECHERT, LLP

Sheila Birnbaum  
Mark S. Cheffo  
Hayden A. Coleman  
Paul A. LaFata  
Jonathan S. Tam  
Erik Snapp  
Three Bryant Park  
1095 Avenue of the Americas  
New York, New York 10036  
sheila.birnbaum@dechert.com  
mark.cheffo@dechert.com  
hayden.coleman@dechert.com  
paul.lafata@dechert.com  
jonathan.tam@dechert.com  
erik.snapp@dechert.com  
*Counsel for Purdue Pharma L.P.,  
Purdue Pharma Inc. and The Purdue  
Frederick Company Inc.*

LYNN PINKER COX & HURST, LLP

Eric Wolf Pinker  
John Thomas Cox III  
Lynn Pinker Cox & Hurst, LLP  
2100 Ross Avenue, Suite 2700  
Dallas, TX 75201  
epinker@lynnllp.com  
tcox@lynnllp.com  
*Counsel for Purdue Pharma L.P.,  
Purdue Pharma Inc. and The Purdue  
Frederick Company Inc.*

GABLEGOTWALS

Robert G. McCampbell

Nicholas V. Merkley

Ashley E. Quinn

One Leadership Square, 15th Fl.

211 North Robinson

Oklahoma City, OK 73102-7255

RMcCampbell@Gablelaw.com

NMerkley@Gablelaw.com

AQuinn@Gablelaw.com

*Attorneys for Defendants Cephalon, Inc., Teva  
Pharmaceuticals USA, Inc., Watson  
Laboratories, Inc., Actavis LLC, and Actavis  
Pharma, Inc. f/k/a/ Watson Pharma, Inc.*

MORGAN, LEWIS & BOCKIUS LLP

Steven A. Reed

Harvey Bartle IV

Rebecca Hillyer

Lindsey T. Mills

1701 Market Street

Philadelphia, PA 19103-2921

steven.reed@morganlewis.com

harvey.bartle@morganlewis.com

rebeccahillyer@morganlewis.com

lindsey.mills@morganlewis.com

*Attorneys for Defendants Cephalon, Inc., Teva  
Pharmaceuticals USA, Inc., Watson  
Laboratories, Inc., Actavis LLC, and Actavis  
Pharma, Inc. f/k/a/ Watson Pharma, Inc.*

MORGAN, LEWIS & BOCKIUS LLP

Brian M. Ercole

200 S. Biscayne Blvd., Suite 5300

Miami, FL 33131

[brian.ercole@morganlewis.com](mailto:brian.ercole@morganlewis.com)

*Attorneys for Defendants Cephalon, Inc., Teva  
Pharmaceuticals USA, Inc., Watson  
Laboratories, Inc., Actavis LLC, and Actavis  
Pharma, Inc. f/k/a/ Watson Pharma, Inc.*

# **EXHIBIT A**

# LYNN PINKER COX HURST

ELIZABETH RYAN  
Partner  
D 214 981 3821  
F 214 981 3839  
eryan@lynnllp.com

Lynn Pinker Cox & Hurst, LLP  
2100 Ross Avenue  
Suite 2700  
Dallas, Texas 75201  
lynnllp.com

February 22, 2019

Mr. Drew Pate  
NIX PATTERSON, LLP  
3600 North Capital of Texas Highway  
Building B, Suite 350  
Austin, Texas 78746

**Re: Deficiencies in the State's Document Production in *State of Oklahoma v. Purdue Pharma L.P., et al.*, Case No. CJ-2017-816, pending in the District Court of Cleveland County, Oklahoma**

Dear Drew:

I write to follow up on (1) my January 23, 2019 e-mail to you regarding the State's failure to produce requested custodial files; (2) the January 24, 2019 conference call that you, Trey Cox, and I had regarding fact witness depositions and custodial file productions; (3) my February 1, 2019 letter to you regarding the State's failure to provide deposition dates and custodial files for multiple witnesses; and (4) my February 14, 2019 e-mail to you requesting deposition dates, custodial files, and various other previously requested documents the State has failed to produce. I have addressed each of the outstanding issues for which we need immediate responses from the State below.

**A. Repeatedly Requested Custodial Files that the State Has Not Yet Produced**

Purdue has repeatedly requested the files from the State for the following custodians. I have included the dates of Purdue's requests below. The State has not yet produced files from these custodians. Note that while you have told me that your firm does not represent a few of the individuals on this list, that does not obviate the State of its obligation to gather responsive documents from these custodians. Furthermore, many of these custodians are deponents in this case and the Court has ordered the State to produce files from deponents in advance of depositions. (*See* 10/18/2018 Order on Purdue's Mot. to Compel Custodial Files in Advance of Depos.; 12/26/2018 Order on Purdue's Motion to Compel.) The State has not complied with those orders. Please

Mr. Drew Pate  
 NIX PATTERSON, LLP  
 February 22, 2019

Page 2

produce all responsive documents that are in the following individuals' possession, custody, and control by 5:00 p.m. Central Time on March 1, 2019.

<b>Custodian</b>	<b>State Agency</b>	<b>Dates Purdue Requested Files</b>
Becky Pasternik-Ikard	Health Care Authority	10/30/2018 Letter 11/26/2018 Letter 12/06/2018 Motion to Compel 01/23/2019 E-mail 01/24/2019 Conference Call 02/01/2019 Letter 02/14/2019 E-mail
Bob Ricks	State Bureau of Investigation	10/30/2018 Letter 11/26/2018 Letter 12/06/2018 Motion to Compel 01/23/2019 E-mail
Carrie Daniels	Department of Mental Health & Substance Abuse Services	10/30/2018 Letter 11/26/2018 Letter 12/06/2018 Motion to Compel 01/23/2019 E-mail 01/24/2019 Conference Call 02/01/2019 Letter 02/14/2019 E-mail
Carrie Evans	Oklahoma Health Care Authority	12/18/2018 Letter 02/01/2019 Letter 02/14/2019 E-mail
Carrie Slatton-Hodges	Department of Mental Health & Substance Abuse Services	10/30/2018 Letter 11/26/2018 Letter 12/06/2018 Motion to Compel 01/23/2019 E-mail 01/24/2019 Conference Call 02/01/2019 Letter 02/14/2019 E-mail
Christopher Shearer	Osteopathic Association; Opioid Overdose Fatality Review Board	02/14/2019 E-mail
Claire Nguyen	State Department of Health	01/21/2019 Letter 02/15/2019 E-mail
Darrell Weaver	Bureau of Narcotics & Dangerous Drugs Control	01/14/2018 E-mail
Deborah Bruce	Board of Osteopathic Examiners	10/30/2018 Letter



Mr. Drew Pate  
 NIX PATTERSON, LLP  
 February 22, 2019

Page 3

<b>Custodian</b>	<b>State Agency</b>	<b>Dates Purdue Requested Files</b>
		11/26/2018 Letter 12/06/2018 Motion to Compel 01/23/2019 E-mail 01/24/2019 Conference Call 02/01/2019 Letter 02/14/2019 E-mail
Diana O'Neal	Office of Management & Enterprise Services	10/30/2018 Letter 11/26/2018 Letter 12/06/2018 Motion to Compel 01/23/2019 E-mail 01/24/2019 Conference Call 02/01/2019 Letter 02/14/2019 E-mail
Don Vogt	Bureau of Narcotics & Dangerous Drugs Control	10/30/2018 Letter 11/26/2018 Letter 12/06/2018 Motion to Compel 01/23/2019 E-mail
Drew Edmondson	Former Attorney General	12/10/2018 Letter 02/01/2019 Letter 02/14/2019 E-mail
Durand Crosby	Department of Mental Health & Substance Abuse Services	10/30/2018 Letter 11/26/2018 Letter 12/06/2018 Motion to Compel 01/23/2019 E-mail 01/24/2019 Conference Call 02/01/2019 Letter 02/14/2019 E-mail
Ed Lake	Department of Human Services; Opioid Overdose Fatality Review Board	02/14/2019 E-mail
Ed Long	Health Care Authority	12/18/2018 Letter 02/01/2019 Letter 02/14/2019 E-mail
Ellen Buettner	Department of Mental Health & Substance Abuse Services	10/30/2018 Letter 11/26/2018 Letter 12/06/2018 Motion to Compel 01/23/2019 E-mail 01/24/2019 Conference Call 02/01/2019 Letter

Mr. Drew Pate  
 NIX PATTERSON, LLP  
 February 22, 2019

Page 4

<b>Custodian</b>	<b>State Agency</b>	<b>Dates Purdue Requested Files</b>
		02/14/2019 E-mail
Ferris Barger	Office of Management & Enterprise Services	10/30/2018 Letter 11/26/2018 Letter 12/06/2018 Motion to Compel 01/23/2019 E-mail 01/24/2019 Conference Call 02/01/2019 Letter 02/14/2019 E-mail
Frank Lawler	Office of Management & Enterprise Services	10/30/2018 Letter 11/26/2018 Letter 12/06/2018 Motion to Compel 01/23/2019 E-mail 01/24/2019 Conference Call 02/01/2019 Letter 02/14/2019 E-mail
Frank Wilson	Office of Management & Enterprise Services	10/30/2018 Letter 12/06/2018 Motion to Compel 01/23/2019 E-mail 01/24/2019 Conference Call 02/01/2019 Letter 02/14/2019 E-mail
Jason Beaman	Oklahoma State University Center for Health Services	10/30/2018 Letter 11/26/2018 Letter 12/06/2018 Motion to Compel 01/23/2019 E-mail
Jean Hausheer	State Medical Association; Opioid Overdose Fatality Review Board	02/14/2019 E-mail
Jessica Hawkins	Department of Mental Health & Substance Abuse Services	10/30/2018 Letter 11/26/2018 Letter 12/06/2018 Motion to Compel 01/23/2019 E-mail 01/24/2019 Conference Call 02/01/2019 Letter 02/14/2019 E-mail
Jill Geiger	Office of State Finance	02/01/2019 02/14/2019
John Scully	Bureau of Narcotics & Dangerous Drugs Control	02/01/2019 Letter 02/14/2019 E-mail

Mr. Drew Pate  
 NIX PATTERSON, LLP  
 February 22, 2019

Page 5

<u>Custodian</u>	<u>State Agency</u>	<u>Dates Purdue Requested Files</u>
Kevin Taubman	Opioid Overdose Fatality Review Board	02/14/2019 E-mail
Liz Massey	Board of Nursing	10/30/2018 Letter 11/26/2018 Letter 12/06/2018 Motion to Compel 01/23/2019 E-mail 01/24/2019 Conference Call 02/01/2019 Letter 02/14/2019 E-mail
Lyle Kesley	Medical Board	02/01/2019 Letter 02/14/2019 E-mail
Lynn Mitchell	State Department of Health; Employees Group Insurance Division Board; Health Care Authority	10/30/2018 Letter 11/26/2018 Letter 12/06/2018 Motion to Compel 01/23/2019 E-mail
Lynne Bajema	Office of Management & Enterprise Services	02/01/2019 Letter 02/14/2019 E-mail
Mark Liotta	Workers' Compensation Commission	10/30/2018 Letter 11/26/2018 Letter 12/06/2018 Motion to Compel 01/23/2019 E-mail
Mark Reynolds	Department of Mental Health & Substance Abuse Services	10/30/2018 Letter 12/06/2018 Motion to Compel 01/23/2019 E-mail 01/24/2019 Conference Call 02/01/2019 Letter 02/14/2019 E-mail
Mark St. Cyr	State Board of Pharmacy	10/30/2018 Letter 11/26/2018 Letter 12/06/2018 Motion to Compel 01/23/2019 E-mail 01/24/2019 Conference Call 02/01/2019 Letter 02/14/2019 E-mail
Mark Stewart	Bureau of Narcotics and Dangerous Drugs Control	10/30/2018 Letter 11/26/2018 Letter 12/06/2018 Motion to Compel 01/23/2019 E-mail

Mr. Drew Pate  
 NIX PATTERSON, LLP  
 February 22, 2019

Page 6

<u>Custodian</u>	<u>State Agency</u>	<u>Dates Purdue Requested Files</u>
Mark Woodward	Bureau of Narcotics & Dangerous Drugs Control	10/30/2018 Letter 11/26/2018 Letter 12/06/2018 Motion to Compel 01/23/2019 E-mail
Mary Fallin	Former Governor	12/10/2018 Letter 02/01/2019 Letter 02/14/2019 E-mail
Mike Fogarty	Health Care Authority	02/14/2019 E-mail
Mike Hunter	Attorney General	12/10/2018 Letter 02/01/2019 Letter 02/14/2019 E-mail
Nichole King	Office of Management & Enterprise Services	10/30/2018 Letter 11/26/2018 Letter 12/06/2018 Motion to Compel 01/23/2019 E-mail 01/24/2019 Conference Call 02/01/2019 Letter 02/14/2019 E-mail
Patricia Sommer	Workers' Compensation Commission	11/26/2018 Letter 12/06/2018 Motion to Compel 01/23/2019 E-mail
Paul King	Office of Management & Enterprise Services	10/30/2018 Letter 11/26/2018 Letter 12/06/2018 Motion to Compel 01/23/2019 E-mail 01/24/2019 Conference Call 02/01/2019 Letter 02/14/2019 E-mail
Reji Varghese	Board of Medical Licensure & Supervision	10/30/2018 Letter 11/26/2018 Letter 12/06/2018 Motion to Compel 01/23/2019 E-mail 01/24/2019 Conference Call 02/01/2019 Letter 02/14/2019 E-mail
Rick Adams	State Bureau of Investigation	02/01/2019 Letter 02/14/2019 E-mail
Scott Pruitt	Former Attorney General	12/10/2018 Letter 02/01/2019 Letter

Mr. Drew Pate  
 NIX PATTERSON, LLP  
 February 22, 2019

Page 7

<u>Custodian</u>	<u>State Agency</u>	<u>Dates Purdue Requested Files</u>
		02/14/2019 E-mail
Stephanie U'ren	State Department of Health	10/30/2018 Letter 11/26/2018 Letter 12/06/2018 Motion to Compel 01/23/2019 E-mail 02/01/2019 Letter 02/14/2019 E-mail
Steven Buck	Office of Juvenile Affairs	10/30/2018 Letter 11/26/2018 Letter 12/06/2018 Motion to Compel 01/23/2019 E-mail 01/24/2019 Conference Call 02/01/2019 Letter 02/14/2019 E-mail
Steven Crawford	Oklahoma Health Care Authority	10/30/2018 Letter 11/26/2018 Letter 12/06/2018 Motion to Compel 01/23/2019 E-mail 01/24/2019 Conference Call
Steven Montgomery	Employees Group Insurance Division Board	10/30/2018 Letter 11/26/2018 Letter 12/06/2018 Motion to Compel 01/23/2019 E-mail 01/24/2019 Conference Call 02/01/2019 Letter 02/14/2019 E-mail
Susan Rogers	State Dental Board; Bureau of Narcotics and Dangerous Drugs Control	10/30/2018 Letter 12/06/2018 Motion to Compel 01/23/2019 E-mail 01/24/2019 Conference Call 02/01/2019 Letter 02/14/2019 E-mail
Sylvia Lopez	Health Care Authority	12/18/2018 Letter 02/01/2019 Letter 02/14/2019 E-mail
Terri White	Department of Mental Health & Substance Abuse Services	10/30/2018 Letter 11/26/2018 Letter 12/06/2018 Motion to Compel 01/23/2019 E-mail

<u>Custodian</u>	<u>State Agency</u>	<u>Dates Purdue Requested Files</u>
Theresa South	Office of Management & Enterprise Services	10/30/2018 Letter 11/26/2018 Letter 12/06/2018 Motion to Compel 01/23/2019 E-mail 01/24/2019 Conference Call 02/01/2019 Letter 02/14/2019 E-mail
Tom Bates	Former Assistant State Attorney General	02/14/2019 E-mail
Travis Tate	Office of Management & Enterprise Services	10/30/2018 Letter 11/26/2018 Letter 12/06/2018 Motion to Compel 01/23/2019 E-mail 01/24/2019 Conference Call 02/01/2019 Letter 02/14/2019 E-mail
Vickie Kersey	Oklahoma Health Care Authority	12/18/2018 Letter 02/01/2019 Letter 02/14/2019 E-mail

**B. Responsive Documents that the State Has Not Produced**

In addition to files from the relevant custodians identified above, the State has not produced the following documents or categories of documents, which are responsive to Purdue's document requests, including document requests that were the subject of (1) the Court's order from April 25, 2018 compelling production; and (2) the Court's order from the January 17, 2019 hearing, which required the State to produce responsive documents by February 5, 2019. The State has not fully complied with those orders. Accordingly, please produce these documents by 5:00 p.m. Central Time on March 1, 2019.

<u>Document or Category of Documents</u>	<u>Notes</u>
Oklahoma Department of Public Safety documents	The Court ordered production on October 4, 2018. The State has not produced these documents.
Oklahoma Drug Threat Assessments	The State has produced only the 2017 report. Purdue reminded the State to produce these

<u>Document or Category of Documents</u>	<u>Notes</u>
	responsive documents on January 7, 2019. At a minimum, these documents are responsive to Purdue Pharma LP's First Requests for Production Nos. 3, 6, and 8.
Medical examiner summaries relied upon in compiling statistics related to overdose deaths in Oklahoma.	Purdue reminded the State to produce these responsive documents on January 21, 2019. At a minimum, these documents are responsive to Purdue Pharma LP's First Requests for Production Nos. 3 and 6.
Dr. Burl Beasley's February 5, 2019 presentation at the Medicaid Innovations Forum in Orlando, Florida, as well as any drafts or related documents.	Purdue reminded the State to produce these responsive documents on February 15, 2019. At a minimum, these documents are responsive to Purdue Pharma LP's First Requests for Production Nos. 6 and 8.
Dr. Burl Beasley's Spring 2018 presentations to the Board of Pharmacy in Oklahoma City and Tulsa, as well as any drafts or related documents.	Purdue reminded the State to produce these responsive documents on February 15, 2019. At a minimum, these documents are responsive to Purdue Pharma LP's First Requests for Production Nos. 6 and 8.
Dr. Burl Beasley's presentation to the Oklahoma Health Care Authority related to the estimated cost of implementing an electronic records system, as well as any drafts or related documents.	Purdue reminded the State to produce these responsive documents on February 15, 2019. At a minimum, these documents are responsive to Purdue Pharma LP's First Requests for Production No. 5.
All contracts between the Oklahoma Health Care Authority and Pharmacy Management Consultants, including all proposals and RFIs from Pharmacy Management Consultants and other interested vendors that were received in connection with those contracts.	Purdue reminded the State to produce these responsive documents on February 15, 2019. At a minimum, these documents are responsive to Purdue Pharma LP's First Requests for Production No. 3 and Purdue Frederick's First Requests for Production No. 3.
All documents related to the Oklahoma Health Care Authority's audit of compounded topical medications and subsequent determination to	Purdue reminded the State to produce these responsive documents on February 15, 2019. At a minimum, these documents are

<b>Document or Category of Documents</b>	<b>Notes</b>
cease coverage and reimbursement for those medications.	responsive to Purdue Pharma LP's First Requests for Production No. 6 and Purdue Pharma Inc.'s First Requests for Production No. 4.
All documents related to the Oklahoma Health Care Authority's ongoing initiative to review Pharmacy Management Consultants' processing of prior authorizations.	Purdue reminded the State to produce these responsive documents on February 15, 2019. At a minimum, these documents are responsive to Purdue Frederick's First Requests for Production Nos. 5, 6, and 7, and Purdue Pharma Inc.'s First Requests for Production Nos. 2 and 3.
Mandatory quarterly reports for the Centers for Disease Control on opioid prescribing statistics, including statistics on high prescribers, doctor shoppers, PDMP alters on conflicting and dangerous prescriptions, none of which contain individualized patient data.	The State has not produced these documents. At a minimum, these documents are responsive to Purdue Pharma LP's First Requests for Production Nos. 3, 6, and 8.
Oklahoma Bureau of Narcotics & Dangerous Drugs Control's diversion reports.	The State has only produced the 2006-2007 report. At a minimum, these documents are responsive to Purdue Pharma LP's First Requests for Production Nos. 3, 6, and 8.
All minutes of meetings of the Oklahoma Board of Dentistry during which opioid medications or diversion of prescription drugs were discussed.	The State has not produced these documents. At a minimum, these documents are responsive to Purdue Pharma LP's First Requests for Production Nos. 6 and 8.
All communications from the Oklahoma Board of Dentistry or its officers addressing draft or proposed legislation related to opioids.	The State has not produced these documents. At a minimum, these documents are responsive to Purdue Pharma LP's First Requests for Production No. 6.
All meetings of minutes for the Drug Utilization Review Board during which opioid medications, diversion of prescription drugs, addiction to prescription drugs, or Medicaid fraud were discussed.	The State has not produced these documents. At a minimum, these documents are responsive to Purdue Pharma LP's First Requests for Production Nos. 2, 6, and 8.



<u>Document or Category of Documents</u>	<u>Notes</u>
All Drug Utilization Review Board Reports.	The State has produced very few of the existing reports. At a minimum, these documents are responsive to Purdue Pharma LP's First Requests for Production Nos. 2, 6, and 8.
Documents within the possession, custody, or control of Employee's Group Insurance Department and the Office of Management and Enterprise Services.	The State has produced only 68 documents from Employee's Group Insurance Department. At a minimum, these documents are responsive to Purdue Pharma LP's First Requests for Production Nos. 6 and 8 and Purdue Frederick's First Requests for Production Nos. 5, 6, and 7.
Oklahoma Bureau of Narcotics and Dangerous Drugs' PowerPoints and public education presentations, including drafts, regarding prescription drugs or opioids.	Mark Woodward testified that he has approximately 24 years of presentations in his possession, which the State has not produced. At a minimum, these documents are responsive to Purdue Pharma LP's First Requests for Production Nos. 6 and 8.
The meeting minutes from any State-sponsored or State-formed group or commission related to opioids, including but not limited to the minutes from the meetings of the groups that met to discuss the opioid prescribing guidelines.	The State has not produced these documents. At a minimum, these documents are responsive to Purdue Pharma LP's First Requests for Production Nos. 6 and 8.

**C. The State's February 21, 2019 Productions**


Finally, I note that yesterday, the State produced documents through approximately sixty-three separate production e-mails and links. Purdue is beginning its review of that production. If you contend the State's most recent production satisfied the State's production obligations that I have addressed here, then please provide me the Bates label ranges for the responsive custodial files, documents, or categories of documents.

Mr. Drew Pate  
NIX PATTERSON, LLP  
February 22, 2019

Page 12

Please contact me if you have any questions.

Thank you,

A handwritten signature in black ink, appearing to read "Elizabeth Yvonne Ryan". The signature is fluid and cursive, with the first name being the most prominent.

Elizabeth Yvonne Ryan

EYR:as

# **EXHIBIT B**

# HealthChoice Standard Medication List

The HealthChoice Standard Medication List is a guide within select therapeutic categories for clients, plan members and health care providers. **Generics should be considered the first line of prescribing.** If there is no generic available, there may be more than one brand-name medicine to treat a condition. These preferred brand-name medicines are listed to help identify products that are clinically appropriate and cost-effective. Generics listed in therapeutic categories are for representational purposes only. This is not an all-inclusive list. This list represents brand products in CAPS, branded generics in upper- and lowercase *italics*, and generic products in lowercase *italics*.

## PLAN MEMBER

HealthChoice provides you with prescription benefits administered by CVS Caremark®. Ask your doctor to consider prescribing, when medically appropriate, a preferred medicine from this list. Take this list along when you or a covered family member sees a doctor.

### Please note:

- Your specific prescription benefit plan design may not cover certain products or categories, regardless of their appearance in this document. Products recently approved by the U.S. Food and Drug Administration (FDA) may not be covered upon release to the market.
- You may be responsible for the full cost of non-formulary products that are removed from coverage.
- For specific information regarding your prescription benefit coverage and copay<sup>1</sup> information, please visit [www.caremark.com](http://www.caremark.com) or contact a CVS Caremark Customer Care representative at 1-877-720-9375. If you have a hearing impairment and need telecommunications device (TDD) assistance, please dial 1-800-863-5488.
- CVS Caremark may contact your doctor after receiving your prescription to request consideration of a drug list product or generic equivalent. This may result in your doctor prescribing, when medically appropriate, a different brand-name product or generic equivalent in place of your original prescription.
- In most instances, a brand-name drug for which a generic product becomes available will be designated as a non-preferred option upon release of the generic product to the market.

## HEALTH CARE PROVIDER

Your patient is covered under HealthChoice prescription benefits administered by CVS Caremark. As a way to help manage health care costs, we encourage you to authorize generic substitutions whenever possible. If you believe a brand-name product is necessary, consider prescribing a brand-name product on this list.

### Please note:

- Generics should be considered the first line of prescribing.
- This drug list represents a summary of prescription coverage. It is not all-inclusive and does not guarantee coverage. HealthChoice prescription benefits may not cover certain products or categories, regardless of their appearance in this document. Products recently approved by the FDA may not be covered upon release to the market.
- HealthChoice may have a different copay<sup>1</sup> for specific products on the list.
- Unless specifically indicated, drug list products will include all dosage forms.
- Log on to [www.caremark.com](http://www.caremark.com) to check coverage and copay<sup>1</sup> information for a specific medicine.

### ANALGESICS

#### § NSAIDs

*diclofenac sodium*  
*meloxicam*  
*naproxen*

#### § NSAIDs, COMBINATIONS

*diclofenac sodium-*  
*misoprostol*

#### § NSAIDs, TOPICAL

*diclofenac sodium gel 1%*  
*diclofenac sodium solution*

#### § COX-2 INHIBITORS

*celecoxib*

#### § GOUT

*allopurinol*  
*colchicine tablet*  
*probenecid*  
COLCRYS

### ULORIC

#### § OPIOID ANALGESICS

*codeine-acetaminophen*  
*fentanyl transdermal*  
*fentanyl transmucosal*  
*lozenge*  
*hydrocodone-acetaminophen*  
*hydromorphone*  
*hydromorphone ext-rel*  
*methadone*  
*morphine*  
*morphine ext-rel*  
*morphine suppository*  
*oxycodone*  
*oxycodone-acetaminophen*  
*tramadol*  
*tramadol ext-rel*  
ABSTRAL  
BELBUCA  
BUTRANS  
EMBEDA

HYSINGLA ER  
NUCYNTA  
NUCYNTA ER  
OXYCONTIN  
SUBSYS

### ANTI-INFECTIVES

#### ANTIBACTERIALS

#### § CEPHALOSPORINS

*cefdinir*  
*cefprozil*  
*cefuroxime axetil*  
*cephalexin*  
SUPRAX

#### § ERYTHROMYCINS / MACROLIDES

*azithromycin*  
*clarithromycin*  
*clarithromycin ext-rel*  
*erythromycins*

### DIFICID

#### § FLUOROQUINOLONES

*ciprofloxacin*  
*ciprofloxacin ext-rel*  
*levofloxacin*  
*moxifloxacin*

#### § PENICILLINS

*amoxicillin*  
*amoxicillin-clavulanate*  
*dicloxacillin*  
*penicillin VK*

#### § TETRACYCLINES

*doxycycline hyclate*  
*minocycline*  
*tetracycline*

#### § ANTIFUNGALS

*fluconazole*  
*itraconazole*

*terbinafine tablet*

#### ANTIVIRALS

§ CYTOMEGALOVIRUS  
AGENTS  
*valganciclovir*

#### § HERPES AGENTS

*acyclovir*  
*valacyclovir*

#### § INFLUENZA AGENTS

*oseltamivir*  
RELENZA

#### § MISCELLANEOUS

*clindamycin*  
*ivermectin*  
*linezolid*  
*metronidazole*  
*nitrofurantoin*  
*sulfamethoxazole-*

trimethoprim  
EMVERM  
XIFAXAN 550 MG

### ANTINEOPLASTIC AGENTS

HORMONAL  
ANTINEOPLASTIC AGENTS

§ ANTIANDROGENS  
bicalutamide

§ MISCELLANEOUS  
VISTOGARD

### CARDIOVASCULAR

§ ACE INHIBITORS

fosinopril  
lisinopril  
quinapril  
ramipril

§ ACE INHIBITOR /  
DIURETIC COMBINATIONS

fosinopril-hydrochlorothiazide  
lisinopril-hydrochlorothiazide  
quinapril-hydrochlorothiazide

§ ANGIOTENSIN II  
RECEPTOR ANTAGONISTS /  
DIURETIC COMBINATIONS

candesartan / candesartan-  
hydrochlorothiazide  
eprosartan  
irbesartan / irbesartan-  
hydrochlorothiazide  
losartan / losartan-  
hydrochlorothiazide  
olmesartan / olmesartan-  
hydrochlorothiazide  
telmisartan / telmisartan-  
hydrochlorothiazide  
valsartan / valsartan-  
hydrochlorothiazide

§ ANGIOTENSIN II  
RECEPTOR ANTAGONIST /  
CALCIUM CHANNEL  
BLOCKER COMBINATIONS

amlodipine-olmesartan  
amlodipine-telmisartan  
amlodipine-valsartan

§ ANGIOTENSIN II  
RECEPTOR ANTAGONIST /  
CALCIUM CHANNEL  
BLOCKER / DIURETIC  
COMBINATIONS

amlodipine-valsartan-  
hydrochlorothiazide  
olmesartan-amlodipine-  
hydrochlorothiazide

§ ANTIARRHYTHMICS  
sotalol  
MULTAQ

ANTILIPEMICS

§ BILE ACID RESINS  
cholestyramine

colesevelam

§ CHOLESTEROL  
ABSORPTION INHIBITORS

ezetimibe

§ FIBRATES

fenofibrate  
fenofibric acid

§ HMG-CoA REDUCTASE  
INHIBITORS /  
COMBINATIONS

atorvastatin  
ezetimibe-simvastatin  
fluvastatin  
lovastatin  
pravastatin  
rosuvastatin  
simvastatin

§ NIACINS

niacin ext-rel

§ OMEGA-3 FATTY ACIDS

omega-3 acid ethyl esters  
VASCEPA

§ BETA-BLOCKERS

atenolol  
carvedilol  
metoprolol succinate ext-rel  
metoprolol tartrate  
nadolol  
pindolol  
propranolol  
propranolol ext-rel  
BYSTOLIC  
COREG CR

§ CALCIUM CHANNEL  
BLOCKERS

amlodipine  
diltiazem ext-rel<sup>2</sup>  
nifedipine ext-rel  
verapamil ext-rel

§ CALCIUM CHANNEL  
BLOCKER / ANTILIPEMIC  
COMBINATIONS

amlodipine-atorvastatin

§ DIGITALIS GLYCOSIDES

digoxin

DIRECT RENIN INHIBITORS /  
DIURETIC COMBINATIONS

TEKTURNA /  
TEKTURNA HCT

§ DIURETICS

amiloride  
furosemide  
hydrochlorothiazide  
metolazone  
spironolactone-  
hydrochlorothiazide  
torsemide  
triamterene-  
hydrochlorothiazide

HEART FAILURE

BIDIL  
CORLANOR  
ENTRESTO

§ NITRATES

nitroglycerin lingual spray  
nitroglycerin sublingual

§ MISCELLANEOUS  
RANEXA

### CENTRAL NERVOUS SYSTEM

§ ANTICONVULSANTS

carbamazepine  
carbamazepine ext-rel  
diazepam rectal gel  
divalproex sodium  
divalproex sodium ext-rel  
ethosuximide  
gabapentin  
lamotrigine  
lamotrigine ext-rel  
levetiracetam  
levetiracetam ext-rel  
oxcarbazepine  
phenobarbital  
phenytoin  
phenytoin sodium extended  
primidone  
tiagabine  
topiramate  
valproic acid  
zonisamide  
FYCOMPA  
OXTELLAR XR  
TROKENDI XR  
VIMPAT

§ ANTIDEMENTIA

donepezil  
galantamine  
galantamine ext-rel  
mementine  
rivastigmine  
rivastigmine transdermal  
NAMZARIC

ANTIDEPRESSANTS

§ SELECTIVE SEROTONIN  
REUPTAKE INHIBITORS  
(SSRIs)

citalopram  
escitalopram  
fluoxetine  
paroxetine HCl  
paroxetine HCl ext-rel  
sertraline  
TRINTELLIX  
VIIBRYD

§ SEROTONIN  
NOREPINEPHRINE  
REUPTAKE INHIBITORS  
(SNRIs)

desvenlafaxine ext-rel  
duloxetine  
venlafaxine  
venlafaxine ext-rel capsule

§ MISCELLANEOUS  
AGENTS

bupropion  
bupropion ext-rel  
mirtazapine  
trazodone

§ ANTIPARKINSONIAN  
AGENTS

amantadine  
carbidopa-levodopa  
carbidopa-levodopa ext-rel  
carbidopa-levodopa-  
entacapone  
entacapone  
pramipexole  
pramipexole ext-rel  
rasagiline  
ropinirole  
ropinirole ext-rel  
selegiline  
NEUPRO

ANTI PSYCHOTICS

§ ATYPICALS

aripiprazole  
clozapine  
olanzapine  
quetiapine  
quetiapine ext-rel  
risperidone  
ziprasidone  
ABILIFY MAINTENA  
ARISTADA  
LATUDA  
VRAYLAR

§ ATTENTION DEFICIT  
HYPERACTIVITY DISORDER

amphetamine-  
dextroamphetamine  
mixed salts  
amphetamine-  
dextroamphetamine  
mixed salts ext-rel  
atomoxetine  
guanfacine ext-rel  
methylphenidate  
methylphenidate ext-rel  
MYDAYIS  
VYVANSE

FIBROMYALGIA

LYRICA  
SAVELLA

HYPNOTICS

§ NONBENZODIAZEPINES

eszopiclone  
zolpidem

zolpidem ext-rel  
zolpidem sublingual  
BELSOMRA

TRICYCLICS

SILENOR

MIGRAINE

§ ERGOTAMINE  
DERIVATIVES

ergotamine-caffeine

§ SELECTIVE SEROTONIN  
AGONISTS

eletriptan  
naratriptan  
rizatriptan  
sumatriptan  
zolmitriptan  
ONZETRA XSAIL  
ZEMBRACE SYMTOUCH  
ZOMIG NASAL SPRAY

SELECTIVE SEROTONIN  
AGONIST / NONSTEROIDAL

ANTI-INFLAMMATORY  
DRUG (NSAID)

COMBINATIONS  
TREXIMET

§ MUSCULOSKELETAL  
THERAPY AGENTS

cyclobenzaprine

§ NARCOLEPSY

armodafinil

POSTHERPETIC  
NEURALGIA (PHN)

GRALISE

PSYCHOTHERAPEUTIC -  
MISCELLANEOUS

§ OPIOID ANTAGONISTS

naloxone injection  
NARCAN NASAL SPRAY

§ PARTIAL OPIOID AGONIST /  
OPIOID ANTAGONIST  
COMBINATIONS

buprenorphine-naloxone  
sublingual tablet  
SUBOXONE FILM  
ZUBSOLV

PSEUDOBULBAR AFFECT  
AGENTS

NUEDEXA

§ VASOMOTOR SYMPTOM  
AGENTS

paroxetine mesylate

### ENDOCRINE AND METABOLIC

§ ANDROGENS

testosterone gel  
testosterone solution  
ANDRODERM  
ANDROGEL 1.62%

ANTIDIABETICS  
AMYLIN ANALOGS  
SYMLINPEN

§ BIGUANIDES  
*metformin*  
*metformin ext-rel*

§ BIGUANIDE /  
SULFONYLUREA  
COMBINATIONS  
*glipizide-metformin*

DIPEPTIDYL PEPTIDASE-4  
(DPP-4) INHIBITORS  
JANUVIA

DIPEPTIDYL PEPTIDASE-4  
(DPP-4) INHIBITOR /  
BIGUANIDE COMBINATIONS  
JANUMET  
JANUMET XR

INCRETIN MIMETIC AGENTS  
OZEMPIC  
TRULICITY  
VICTOZA

INCRETIN MIMETIC AGENT /  
INSULIN COMBINATIONS  
SOLIQUA

INSULINS  
BASAGLAR  
FIASP  
HUMULIN R U-500  
LEVEMIR  
NOVOLIN 70/30  
NOVOLIN N  
NOVOLIN R  
NOVOLOG  
NOVOLOG MIX 70/30  
TRESIBA

§ INSULIN SENSITIZERS  
*pioglitazone*

§ INSULIN SENSITIZER /  
BIGUANIDE COMBINATIONS  
*pioglitazone-metformin*

§ INSULIN SENSITIZER /  
SULFONYLUREA  
COMBINATIONS  
*pioglitazone-glimepiride*

§ MEGLITINIDES  
*nateglinide*  
*repaglinide*

SODIUM-GLUCOSE  
CO-TRANSPORTER 2  
(SGLT2) INHIBITORS  
FARXIGA  
JARDIANCE

SODIUM-GLUCOSE  
CO-TRANSPORTER 2  
(SGLT2) INHIBITOR /  
BIGUANIDE COMBINATIONS  
SYNJARDY

SYNJARDY XR  
XIGDUO XR

SODIUM-GLUCOSE  
CO-TRANSPORTER 2  
(SGLT2) INHIBITOR /  
DIPEPTIDYL PEPTIDASE-4  
(DPP-4) INHIBITOR  
COMBINATIONS  
GLYXAMBI  
QTERN

§ SULFONYLUREAS  
*glimepiride*  
*glipizide*  
*glipizide ext-rel*

SUPPLIES  
ACCU-CHEK AVIVA PLUS  
STRIPS AND KITS<sup>3</sup>  
ACCU-CHEK COMPACT  
PLUS STRIPS AND KITS<sup>3</sup>  
ACCU-CHEK GUIDE  
STRIPS AND KITS<sup>3</sup>  
ACCU-CHEK SMARTVIEW  
STRIPS AND KITS<sup>3</sup>  
BD ULTRAFINE INSULIN  
SYRINGES AND  
NEEDLES

CALCIUM REGULATORS  
§ BISPHOSPHONATES  
*alendronate*  
*ibandronate*  
*risedronate*

§ CALCITONINS  
*calcitonin-salmon*

§ CARNITINE DEFICIENCY  
AGENTS  
*levocarnitine*

CONTRACEPTIVES

§ MONOPHASIC  
*ethinyl estradiol-  
drospirenone*  
*ethinyl estradiol-  
drospirenone-levomefolate*  
*ethinyl estradiol-  
norethindrone acetate*  
*ethinyl estradiol-  
norethindrone acetate-iron*  
SAFYRAL

§ BIPHASIC  
LO LOESTRIN FE

§ TRIPHASIC  
*ethinyl estradiol-norgestimate*

FOUR PHASE  
NATAZIA

§ EXTENDED CYCLE  
*ethinyl estradiol-  
levonorgestrel*

§ TRANSDERMAL  
*ethinyl estradiol-  
norelgestromin*

VAGINAL  
NUVARING

ESTROGENS  
§ ORAL  
*estradiol*  
*estropipate*  
PREMARIN

§ TRANSDERMAL  
*estradiol*  
DIVIGEL  
EVAMIST  
MINIVELLE

§ VAGINAL  
*estradiol*  
ESTRACE CREAM  
ESTRING  
PREMARIN CREAM

ESTROGEN / PROGESTINS  
§ ORAL  
*estradiol-norethindrone*  
PREMPHASE  
PREMPRO

TRANSDERMAL  
CLIMARA PRO  
COMBIPATCH

ESTROGEN / SELECTIVE  
ESTROGEN RECEPTOR  
MODULATOR  
COMBINATIONS  
DUAVEE

§ GLUCOCORTICOIDS  
*dexamethasone*  
*methylprednisolone*  
*prednisolone solution*  
*prednisone*

GLUCOSE ELEVATING  
AGENTS  
GLUCAGEN HYPOKIT  
GLUCAGEN EMERGENCY  
KIT

§ PHOSPHATE BINDER  
AGENTS  
*calcium acetate*  
*lanthanum carbonate*  
*sevelamer carbonate*  
PHOSLYRA  
VELPHORO

POTASSIUM-REMOVING  
AGENTS  
VELTASSA

PROGESTINS  
§ ORAL  
*medroxyprogesterone*  
*megestrol acetate*  
*progesterone, micronized*

VAGINAL  
CRINONE  
ENDOMETRIN

§ SELECTIVE ESTROGEN  
RECEPTOR MODULATORS  
*raloxifene*  
OSPHENA

§ THYROID SUPPLEMENTS  
*levothyroxine*  
SYNTHROID

## GASTROINTESTINAL

§ ANTIEMETICS  
*dronabinol*  
*granisetron*  
*metoclopramide*  
*ondansetron*  
*prochlorperazine*  
*promethazine*  
*trimethobenzamide*  
DICLEGIS  
SANCUSO  
VARUBI

§ H<sub>2</sub> RECEPTOR  
ANTAGONISTS  
*ranitidine*

INFLAMMATORY BOWEL  
DISEASE

§ ORAL AGENTS  
*balsalazide*  
*budesonide capsule*  
*sulfasalazine*  
*sulfasalazine delayed-rel*  
APRISO  
LIALDA  
PENTASA  
UCERIS

§ RECTAL AGENTS  
*hydrocortisone enema*  
*mesalamine rectal  
suspension*  
CANASA  
CORTIFOAM

§ IRRITABLE BOWEL  
SYNDROME  
*alosetron*  
AMITIZA  
LINZESS  
VIBERZI

§ LAXATIVES  
*lactulose*  
*peg 3350-electrolytes*  
SUPREP

OPIOID-INDUCED  
CONSTIPATION  
MOVANTIK

PANCREATIC ENZYMES  
CREON  
VIKACE

ZENPEP

§ PROTON PUMP  
INHIBITORS  
*esomeprazole*  
*lansoprazole*  
*omeprazole*  
*pantoprazole*  
DEXILANT

§ STEROIDS, RECTAL  
PROCTOFOAM-HC

§ ULCER THERAPY  
COMBINATIONS  
PYLERA

## GENITOURINARY

§ BENIGN PROSTATIC  
HYPERPLASIA  
*alfuzosin ext-rel*  
*doxazosin*  
*dutasteride*  
*dutasteride-tamsulosin*  
*finasteride*  
*tamsulosin*  
*terazosin*  
RAPAFLO

§ URINARY  
ANTISPASMODICS  
*darifenacin ext-rel*  
*oxybutynin*  
*oxybutynin ext-rel*  
*tolterodine*  
*tolterodine ext-rel*  
*trospium*  
*trospium ext-rel*  
MYRBETRIQ  
TOVIAZ  
VESICARE

## HEMATOLOGIC

§ ANTICOAGULANTS  
*warfarin*  
ELIQUIS  
XARELTO

§ PLATELET AGGREGATION  
INHIBITORS  
*clopidogrel*  
*dipyridamole ext-rel-aspirin*  
*prasugrel*  
BRILINTA

## IMMUNOLOGIC AGENTS

ALLERGENIC EXTRACTS  
GRASTEK  
RAGWITEK

## NUTRITIONAL / SUPPLEMENTS

§ ELECTROLYTES  
*potassium chloride liquid*

**VITAMINS AND MINERALS****§ PRENATAL VITAMINS**

*prenatal vitamins*  
CITRANATAL

**RESPIRATORY****§ ANAPHYLAXIS TREATMENT AGENTS**

*epinephrine auto-injector*  
EPIPEN  
EPIPEN JR

**§ ANTICHOLINERGICS**

*ipratropium inhalation solution*  
INCRUSE ELLIPTA  
SPIRIVA

**ANTICHOLINERGIC / BETA AGONIST COMBINATIONS****§ SHORT ACTING**

*ipratropium-albuterol inhalation solution*  
COMBIVENT RESPIMAT

**LONG ACTING**

ANORO ELLIPTA  
BEVESPI AEROSPHERE  
STIOLTO RESPIMAT

**ANTICHOLINERGIC / BETA AGONIST / STEROID INHALANT COMBINATIONS**

TRELEGY ELLIPTA

**BETA AGONISTS, INHALANTS****§ SHORT ACTING**

*albuterol inhalation solution*  
*levosalbuterol tartrate CFC-free aerosol*  
PROAIR HFA  
PROAIR RESPICLICK

**LONG ACTING****Hand-held Active Inhalation**

SEREVENT  
STRIVERDI RESPIMAT

**Nebulized Passive Inhalation**

PERFOROMIST

**§ LEUKOTRIENE MODULATORS**

*montelukast*  
*zafirlukast*  
*zileuton ext-rel*

**§ NASAL ANTIHISTAMINES**

*azelastine*  
*olopatadine*

**§ NASAL STEROIDS / COMBINATIONS**

*flunisolide*  
*fluticasone*  
*mometasone*  
*triamcinolone*  
DYMISTA

**PHOSPHODIESTERASE-4 INHIBITORS**

DALIRESP

**STEROID / BETA AGONIST COMBINATIONS**

ADVAIR  
BREQ ELLIPTA  
SYMBICORT

**§ STEROID INHALANTS**

*budesonide inhalation suspension*  
ARNUITY ELLIPTA  
ASMANEX  
FLOVENT DISKUS  
FLOVENT HFA  
PULMICORT FLEXHALER  
QVAR  
QVAR REDHALER

**TOPICAL****DERMATOLOGY****ACNE****§ Topical**

*adapalene*  
*benzoyl peroxide*  
*clindamycin solution*  
*clindamycin-benzoyl peroxide*  
*erythromycin solution*  
*erythromycin-benzoyl peroxide*  
*tretinoin*  
ATRALIN  
DIFFERIN

EPIDUO  
RETIN-A MICRO  
TAZORAC

**§ ACTINIC KERATOSIS**

*fluorouracil cream 5%*  
*fluorouracil solution*  
*imiquimod*  
PICATO  
TOLAK  
ZYCLARA

**§ ANTIFUNGALS**

*ciclopirox*  
*clotrimazole*  
*econazole*  
*ketoconazole*  
*nystatin*  
JUBLIA  
LUZU  
NAFTIN

**§ ANTIPSORIATICS**

*acitretin*  
*calcipotriene*  
*methoxsalen*

**§ ATOPIC DERMATITIS**

*tacrolimus*  
ELIDEL  
EUCRISA

**CORTICOSTEROIDS****§ Low Potency**

*desonide*  
*hydrocortisone*

**§ Medium Potency**

*clocortolone*  
*hydrocortisone butyrate*  
*mometasone*  
*triamcinolone*

**§ High Potency**

*desoximetasone*  
*fluocinonide*

**§ Very High Potency**

*clobetasol cream, foam, gel, lotion, ointment, shampoo*

**§ ROSACEA**

*metronidazole*  
FINACEA  
ORACEA

SOOLANTRA

**MOUTH / THROAT / DENTAL AGENTS****PROTECTANTS EPISIL****OPHTHALMIC § ANTIALLERGICS**

*azelastine*  
*cromolyn sodium*  
*olopatadine*  
LASTACAPT  
PAZEO

**§ ANTI-INFECTIVES**

*ciprofloxacin*  
*erythromycin*  
*gentamicin*  
*levofloxacin*  
*moxifloxacin*  
*ofloxacin*  
*sulfacetamide*  
*tobramycin*  
BESIVANCE  
CILOXAN OINTMENT  
MOXEZA

**§ ANTI-INFECTIVE / ANTI-INFLAMMATORY COMBINATIONS**

*neomycin-polymyxin B-bacitracin-hydrocortisone*  
*neomycin-polymyxin B-dexamethasone*  
*tobramycin-dexamethasone*  
TOBRADEX OINTMENT  
TOBRADEX ST  
ZYLET

**ANTI-INFLAMMATORIES****§ Nonsteroidal**

*bromfenac*  
*diclofenac*  
*ketorolac*  
ACUVAIL  
ILEVRO  
NEVANAC

**§ Steroidal**

*dexamethasone*  
*prednisolone acetate 1%*  
DUREZOL  
FLAREX

FML FORTE  
FML S.O.P.  
MAXIDEX  
PRED MILD

**BETA-BLOCKERS****§ Nonselective**

*timolol maleate solution*  
BETIMOL

**Selective**

BETOPTIC S

**§ CARBONIC ANHYDRASE INHIBITORS**

*dorzolamide*  
AZOPT

**§ CARBONIC ANHYDRASE INHIBITOR / BETA-BLOCKER COMBINATIONS**

*dorzolamide-timolol*

**CARBONIC ANHYDRASE INHIBITOR / SYMPATHOMIMETIC COMBINATIONS**

SIMBRINZA

**DRY EYE DISEASE**

RESTASIS  
XIIDRA

**§ PROSTAGLANDINS**

*latanoprost*  
LUMIGAN  
TRAVATAN Z

**RHO KINASE INHIBITORS**

RHOPRESSA

**§ SYMPATHOMIMETICS**

*brimonidine*  
ALPHAGAN P

**SYMPATHOMIMETIC / BETA-BLOCKER COMBINATIONS**

COMBIGAN

**OTIC****§ ANTI-INFECTIVE / ANTI-INFLAMMATORY COMBINATIONS**

CIPRODEX

**QUICK REFERENCE DRUG LIST****A**

ABILIFY MAINTENA  
ABSTRAL  
ACCU-CHEK AVIVA PLUS STRIPS AND KITS<sup>3</sup>  
ACCU-CHEK COMPACT PLUS STRIPS AND KITS<sup>3</sup>  
ACCU-CHEK GUIDE STRIPS AND KITS<sup>3</sup>  
ACCU-CHEK SMARTVIEW STRIPS AND KITS<sup>3</sup>

*acitretin*  
ACUVAIL  
*acyclovir*  
*adapalene*  
ADVAIR  
*albuterol inhalation solution*  
*alendronate*  
*afuzosin ext-rel*  
*allopurinol*  
*alosetron*  
ALPHAGAN P

*amantadine*  
*amiloride*  
AMITIZA  
*amlodipine*  
*amlodipine-atorvastatin*  
*amlodipine-olmesartan*  
*amlodipine-telmisartan*  
*amlodipine-valsartan*  
*amlodipine-valsartan-hydrochlorothiazide*  
*amoxicillin*

*amoxicillin-clavulanate*  
*amphetamine-dextroamphetamine mixed salts*  
*amphetamine-dextroamphetamine mixed salts ext-rel*  
ANDRODERM  
ANDROGEL 1.62%  
ANORO ELLIPTA  
APRISO

*aripiprazole*  
ARISTADA  
*armodafinil*  
ARNUITY ELLIPTA  
ASMANEX  
*atenolol*  
*atomoxetine*  
*atorvastatin*  
ATRALIN  
*azelastine*  
*azithromycin*

AZOPT

**B**

balsalazide  
BASAGLAR  
BD ULTRAFINE INSULIN  
SYRINGES AND  
NEEDLES  
BELBUCA  
BELSOMRA  
benzoyl peroxide  
BESIVANCE  
BETIMOL  
BETOPTIC S  
BEVESPI AEROSPHERE  
bicalutamide  
BIDIL  
BREO ELLIPTA  
BRILINTA  
brimonidine  
bromfenac  
budesonide capsule  
budesonide inhalation  
suspension  
buprenorphine-naloxone  
sublingual tablet  
bupropion  
bupropion ext-rel  
BUTRANS  
BYSTOLIC

**C**

calcipotriene  
calcitonin-salmon  
calcium acetate  
CANASA  
candesartan  
candesartan-  
hydrochlorothiazide  
carbamazepine  
carbamazepine ext-rel  
carbidopa-levodopa  
carbidopa-levodopa ext-rel  
carbidopa-levodopa-  
entacapone  
carvedilol  
cefdinir  
cefprozil  
cefuroxime axetil  
celecoxib  
cephalexin  
cholestyramine  
ciclopirox  
CILOXAN OINTMENT  
CIPRODEX  
ciprofloxacin  
ciprofloxacin ext-rel  
citalopram  
CITRANATAL  
clarithromycin  
clarithromycin ext-rel  
CLIMARA PRO  
clindamycin  
clindamycin solution  
clindamycin-benzoyl  
peroxide  
clobetasol cream, foam, gel,  
lotion, ointment, shampoo  
clocortolone

clopidogrel  
clotrimazole  
clozapine  
codeine-acetaminophen  
colchicine tablet  
COLCRYS  
colesevelam  
COMBIGAN  
COMBIPATCH  
COMBIVENT RESPIMAT  
COREG CR  
CORLANOR  
CORTIFOAM  
CREON  
CREON  
CRINONE  
cromolyn sodium  
cyclobenzaprine

**D**

DALIRESP  
darifenacin ext-rel  
desonide  
desoximetasone  
desvenlafaxine ext-rel  
dexamethasone  
DEXILANT  
diazepam rectal gel  
DICLEGIS  
diclofenac  
diclofenac sodium  
diclofenac sodium gel 1%  
diclofenac sodium solution  
diclofenac sodium-  
misoprostol  
dicloxacillin  
DIFFERIN  
DIFICID  
digoxin  
diiltiazem ext-rel<sup>2</sup>  
dipyridamole ext-rel-aspirin  
divalproex sodium  
divalproex sodium ext-rel  
DIVIGEL  
donepezil  
dorzolamide  
dorzolamide-timolol  
doxazosin  
doxycycline hyclate  
dronabinol  
DUAVEE  
duloxetine  
DUREZOL  
dutasteride  
dutasteride-tamsulosin  
DYMISTA

**E**

econazole  
eletriptan  
ELIDEL  
ELIQUIS  
EMBEDA  
EMVERM  
ENDOMETRIN  
entacapone  
ENTRESTO  
EPIDUO  
epinephrine auto-injector  
EPIPEN

EPIPEN JR  
EPISIL  
eprosartan  
ergotamine-caffeine  
erythromycin  
erythromycin solution  
erythromycin-benzoyl  
peroxide  
erythromycins  
escitalopram  
esomeprazole  
ESTRACE CREAM  
estradiol  
estradiol-norethindrone  
ESTRING  
estropipate  
eszopiclone  
ethinyl estradiol-  
drospirenone  
ethinyl estradiol-  
drospirenone-levomefolate  
ethinyl estradiol-  
levonorgestrel  
ethinyl estradiol-  
norelgestromin  
ethinyl estradiol-  
norethindrone acetate  
ethinyl estradiol-  
norethindrone acetate-iron  
ethinyl estradiol-norgestimate  
ethosuximide  
EUCRISA  
EVAMIST  
ezetimibe  
ezetimibe-simvastatin

**F**

FARXIGA  
fenofibrate  
fenofibric acid  
fentanyl transdermal  
fentanyl transmucosal  
lozeng  
FIASP  
FINACEA  
finasteride  
FLAREX  
FLOVENT DISKUS  
FLOVENT HFA  
fluconazole  
flunisolide  
fluocinonide  
fluorouracil cream 5%  
fluorouracil solution  
fluoxetine  
fluticasone  
fluvastatin  
FML FORTE  
FML S.O.P.  
fosinopril  
fosinopril-hydrochlorothiazide  
furosemide  
FYCOMPA

**G**

gabapentin  
galantamine  
galantamine ext-rel  
gentamicin

glimepiride  
glipizide  
glipizide ext-rel  
glipizide-metformin  
GLUCAGEN HYPOKIT  
GLUCAGON EMERGENCY  
KIT  
GLYXAMBI  
GRALISE  
granisetron  
GRASTEK  
guanfacine ext-rel

**H**

HUMULIN R U-500  
hydrochlorothiazide  
hydrocodone-acetaminophen  
hydrocortisone  
hydrocortisone butyrate  
hydrocortisone enema  
hydromorphone  
hydromorphone ext-rel  
HYSINGLA ER

**I**

ibandronate  
ILEVRO  
imiquimod  
INCRUSE ELLIPTA  
ipratropium inhalation  
solution  
ipratropium-albuterol  
inhalation solution  
irbesartan  
irbesartan-  
hydrochlorothiazide  
itraconazole  
ivermectin

**J**

JANUMET  
JANUMET XR  
JANUVIA  
JARDIANCE  
JUBLIA

**K**

ketoconazole  
ketorolac

**L**

lactulose  
lamotrigine  
lamotrigine ext-rel  
lansoprazole  
lanthanum carbonate  
LASTACAPT  
latanoprost  
LATUDA  
levalbuterol tartrate CFC-free  
aerosol  
LEVEMIR  
levetiracetam  
levetiracetam ext-rel  
levocarnitine  
levofloxacin  
levothyroxine  
LIALDA  
linezolid

LINZESS  
lisinopril  
lisinopril-hydrochlorothiazide  
LO LOESTRIN FE  
losartan  
losartan-hydrochlorothiazide  
lovastatin  
LUMIGAN  
LUZU  
LYRICA

**M**

MAXIDEX  
meclizine  
medroxyprogesterone  
megestrol acetate  
meloxicam  
memantine  
mesalamine rectal  
suspension  
metformin  
metformin ext-rel  
methadone  
methoxsalen  
methylphenidate  
methylphenidate ext-rel  
methylprednisolone  
metoclopramide  
metolazone  
metoprolol succinate ext-rel  
metoprolol tartrate  
metronidazole  
MINIVELLE  
minocycline  
mirtazapine  
mometasone  
montelukast  
morphine  
morphine ext-rel  
morphine suppository  
MOVANTIK  
MOXEZA  
moxifloxacin  
MULTAQ  
MYDAYIS  
MYRBETRIQ

**N**

nadolol  
NAFTIN  
naloxone injection  
NAMZARIC  
naproxen  
naratriptan  
NARCAN NASAL SPRAY  
NATAZIA  
nateglinide  
neomycin-polymyxin B-  
bacitracin-hydrocortisone  
neomycin-polymyxin B-  
dexamethasone  
NEUPRO  
NEVANAC  
niacin ext-rel  
nifedipine ext-rel  
nitrofurantoin  
nitroglycerin lingual spray  
nitroglycerin sublingual  
NOVOLIN 70/30



NOVOLIN N  
NOVOLIN R  
NOVOLOG  
NOVOLOG MIX 70/30  
NUCYNTA  
NUCYNTA ER  
NUDEXTA  
NUVARING  
nystatin

**O**

ofloxacin  
olanzapine  
olmesartan  
olmesartan-amlodipine-  
hydrochlorothiazide  
olmesartan-  
hydrochlorothiazide  
oloppatadine  
omega-3 acid ethyl esters  
omeprazole  
ondansetron  
ONZETRA XSAIL  
ORACEA  
oseltamivir  
OSPHENA  
oxcarbazepine  
OXTELLAR XR  
oxybutynin  
oxybutynin ext-rel  
oxycodone  
oxycodone-acetaminophen  
OXYCONTIN  
OZEMPIC

**P**

pantoprazole  
paroxetine HCl  
paroxetine HCl ext-rel  
paroxetine mesylate  
PAZEO  
peg 3350-electrolytes  
penicillin VK  
PENTASA  
PERFOROMIST  
phenobarbital  
phenytoin  
phenytoin sodium extended  
PHOSLYRA

PICATO  
pindolol  
pioglitazone  
pioglitazone-glimepiride  
pioglitazone-metformin  
potassium chloride liquid  
pramipexole  
pramipexole ext-rel  
prasugrel  
pravastatin  
PRED MILD  
prednisolone acetate 1%  
prednisolone solution  
prednisone  
PREMARIN  
PREMARIN CREAM  
PREMPHASE  
PREMPRO  
prenatal vitamins  
primidone  
PROAIR HFA  
PROAIR RESPICLICK  
probenecid  
prochlorperazine  
PROCTOFOAM-HC  
progesterone, micronized  
promethazine  
propranolol  
propranolol ext-rel  
PULMICORT FLEXHALER  
PYLERA

**Q**

QTERN  
quetiapine  
quetiapine ext-rel  
quinapril  
quinapril-hydrochlorothiazide  
QVAR  
QVAR REDIHALER

**R**

RAGWITEK  
raloxifene  
ramipril  
RANEXA  
ranitidine  
RAPAFLO  
rasagiline

RELENZA  
repaglinide  
RESTASIS  
RETIN-A MICRO  
RHOPRESSA  
risedronate  
risperidone  
rivastigmine  
rivastigmine transdermal  
rizatriptan  
ropinirole  
ropinirole ext-rel  
rosuvastatin

**S**

SAFYRAL  
SANCUSO  
SAVELLA  
selegiline  
SEREVENT  
sertraline  
sevelamer carbonate  
SILENOR  
SIMBRINZA  
simvastatin  
SOLQUA  
SOOLANTRA  
sotalol  
SPIRIVA  
spironolactone-  
hydrochlorothiazide  
STIOLTO RESPIMAT  
STRIVERDI RESPIMAT  
SUBOXONE FILM  
SUBSYS  
sulfacetamide  
sulfamethoxazole-  
trimethoprim  
sulfasalazine  
sulfasalazine delayed-rel  
sumatriptan  
SUPRAX  
SUPREP  
SYMBICORT  
SYMLINPEN  
SYNJARDY  
SYNJARDY XR  
SYNTHROID

**T**

tacrolimus  
tamsulosin  
TAZORAC  
TEKTURNA  
TEKTURNA HCT  
telmisartan  
telmisartan-  
hydrochlorothiazide  
terazosin  
terbinafine tablet  
testosterone gel  
testosterone solution  
tetracycline  
tiagabine  
timolol maleate solution  
TOBRADEX OINTMENT  
TOBRADEX ST  
tobramycin  
tobramycin-dexamethasone  
TOLAK  
tolterodine  
tolterodine ext-rel  
topiramate  
torsemide  
TOVIAZ  
tramadol  
tramadol ext-rel  
TRAVATAN Z  
trazodone  
TRELEGY ELLIPTA  
TRESIBA  
tretinoin  
TREXIMET  
triamcinolone  
triamterene-  
hydrochlorothiazide  
trimethobenzamide  
TRINTELLIX  
TROKENDI XR  
trospium  
trospium ext-rel  
TRULICITY

**U**

UCERIS  
ULORIC

**V**

valacyclovir  
valganciclovir  
valproic acid  
valsartan  
valsartan-hydrochlorothiazide  
VARUBI  
VASCEPA  
VELPHORO  
VELTASSA  
venlafaxine  
venlafaxine ext-rel capsule  
verapamil ext-rel  
VESICARE  
VIBERZI  
VICTOZA  
VIBRYD  
VIMPAT  
VIOKACE  
VISTOGARD  
VRAYLAR  
VYVANSE

**W**

warfarin

**X**

XARELTO  
XIFAXAN 550 MG  
XIGDUO XR  
XIIDRA

**Z**

zafirlukast  
ZEMBRACE SYMTOUCH  
ZENPEP  
zileuton ext-rel  
ziprasidone  
zolmitriptan  
zolpidem  
zolpidem ext-rel  
zolpidem sublingual  
ZOMIG NASAL SPRAY  
zonisamide  
ZUBSOLV  
ZYCLARA  
ZYLET

**PREFERRED OPTIONS LIST**

DRUG NAME(S)	PREFERRED OPTION(S)*	DRUG NAME(S)	PREFERRED OPTION(S)*
ABILIFY	aripiprazole, clozapine, olanzapine, quetiapine, quetiapine ext-rel, risperidone, ziprasidone, LATUDA, VRAYLAR	ALEVICYN GEL, ALEVICYN KIT, ALEVICYN SG, Alevicyc solution	desonide, hydrocortisone
ACANYA	adapalene, benzoyl peroxide, clindamycin solution, clindamycin-benzoyl peroxide, erythromycin solution, erythromycin-benzoyl peroxide, tretinoin, ATRALIN, DIFFERIN, EPIDUO, RETIN-A MICRO, TAZORAC	ALLISON MEDICAL INSULIN SYRINGES <sup>5</sup>	BD ULTRAFINE INSULIN SYRINGES
ACTICLATE	doxycycline hyclate	ALORA	estradiol, DIVIGEL, EVAMIST, MINIVELLE
ACTOS	pioglitazone	ALTOPREV	atorvastatin, ezetimibe-simvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin
ADDERALL XR	amphetamine-dextroamphetamine mixed salts ext-rel, methylphenidate ext-rel, MYDAYIS, VYVANSE	ALVESCO	ARNUITY ELLIPTA, ASMANEX, FLOVENT DISKUS, FLOVENT HFA, PULMICORT FLEXHALER, QVAR, QVAR REDIHALER
ALCORTIN A	desonide, hydrocortisone	AMRIX	cyclobenzaprine
		ANDROGEL 1%	testosterone gel, testosterone solution, ANDRODERM, ANDROGEL 1.62%

Your specific prescription benefit plan design may not cover certain products or categories, regardless of their appearance in this document. For specific information, visit [www.caremark.com](http://www.caremark.com) or contact a CVS Caremark Customer Care representative.

DRUG NAME(S)	PREFERRED OPTION(S)*	DRUG NAME(S)	PREFERRED OPTION(S)*
ANGELIQ	estradiol-norethindrone, PREMPHASE, PREMPRO	CAFERGOT	eletriptan, ergotamine-caffeine, naratriptan, rizatriptan, sumatriptan, zolmitriptan, ONZETRA XSAIL, ZEMBRACE SYMTOUCH, ZOMIG NASAL SPRAY
ANTARA	fenofibrate, fenofibric acid	CAMBIA	diclofenac sodium, meloxicam, naproxen
APEXICON E	desoximetasone, fluocinonide	CARAC	fluorouracil cream 5%, fluorouracil solution, imiquimod, PICATO, TOLAK, ZYCLARA
APIDRA	FIASP, NOVOLOG	CARDIZEM	diltiazem ext-rel (except generic CARDIZEM LA)
ARMOUR THYROID	levothyroxine, SYNTHROID	CARDIZEM CD	diltiazem ext-rel (except generic CARDIZEM LA)
ARTHROTEC	celecoxib; diclofenac sodium, meloxicam or naproxen WITH esomeprazole, lansoprazole, omeprazole, pantoprazole or DEXILANT	CARDIZEM LA (and its generics)	diltiazem ext-rel (except generic CARDIZEM LA)
ASACOL HD	balsalazide, sulfasalazine, sulfasalazine delayed-rel, APRISO, LIALDA, PENTASA	CARNITOR	levocarnitine
ASCENSIA STRIPS AND KITS 4	ACCU-CHEK AVIVA PLUS STRIPS AND KITS 3, ACCU-CHEK COMPACT PLUS STRIPS AND KITS 3, ACCU-CHEK GUIDE STRIPS AND KITS 3, ACCU-CHEK SMARTVIEW STRIPS AND KITS 3	CARNITOR SF	levocarnitine
ATACAND, ATACAND HCT	candesartan, candesartan-hydrochlorothiazide, eprosartan, irbesartan, irbesartan-hydrochlorothiazide, losartan, losartan-hydrochlorothiazide, olmesartan, olmesartan-hydrochlorothiazide, telmisartan, telmisartan-hydrochlorothiazide, valsartan, valsartan-hydrochlorothiazide	CLINDAGEL	erythromycin solution
ATROVENT HFA	ipratropium inhalation solution, INCRUSE ELLIPTA, SPIRIVA	clobetasol spray	clobetasol foam
AVENOVA	Consult doctor	CLOBEX SPRAY	clobetasol foam
AXERT	eletriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan, ONZETRA XSAIL, ZEMBRACE SYMTOUCH, ZOMIG NASAL SPRAY	COLAZAL	balsalazide
AZELEX	adapalene, benzoyl peroxide, clindamycin solution, clindamycin-benzoyl peroxide, erythromycin solution, erythromycin-benzoyl peroxide, tretinoin, ATRALIN, DIFFERIN, EPIDUO, RETIN-A MICRO, TAZORAC	CONTOUR NEXT STRIPS AND KITS 4	ACCU-CHEK AVIVA PLUS STRIPS AND KITS 3, ACCU-CHEK COMPACT PLUS STRIPS AND KITS 3, ACCU-CHEK GUIDE STRIPS AND KITS 3, ACCU-CHEK SMARTVIEW STRIPS AND KITS 3
BECONASE AQ	fluticasone, fluticasone, mometasone, triamcinolone, DYMISTA	CONTOUR STRIPS AND KITS 4	ACCU-CHEK AVIVA PLUS STRIPS AND KITS 3, ACCU-CHEK COMPACT PLUS STRIPS AND KITS 3, ACCU-CHEK GUIDE STRIPS AND KITS 3, ACCU-CHEK SMARTVIEW STRIPS AND KITS 3
BENICAR, BENICAR HCT	candesartan, candesartan-hydrochlorothiazide, eprosartan, irbesartan, irbesartan-hydrochlorothiazide, losartan, losartan-hydrochlorothiazide, olmesartan, olmesartan-hydrochlorothiazide, telmisartan, telmisartan-hydrochlorothiazide, valsartan, valsartan-hydrochlorothiazide	CRESTOR	atorvastatin, ezetimibe-simvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin
BENSAL HP	desonide, hydrocortisone	CYMBALTA	desvenlafaxine ext-rel, duloxetine, venlafaxine, venlafaxine ext-rel capsule
BENZAC AC	adapalene, benzoyl peroxide, clindamycin solution, clindamycin-benzoyl peroxide, erythromycin solution, erythromycin-benzoyl peroxide, tretinoin, ATRALIN, DIFFERIN, EPIDUO, RETIN-A MICRO, TAZORAC	DELZICOL	balsalazide, sulfasalazine, sulfasalazine delayed-rel, APRISO, LIALDA, PENTASA
BENZACLIN	adapalene, benzoyl peroxide, clindamycin solution, clindamycin-benzoyl peroxide, erythromycin solution, erythromycin-benzoyl peroxide, tretinoin, ATRALIN, DIFFERIN, EPIDUO, RETIN-A MICRO, TAZORAC	DETROL LA	darifenacin ext-rel, oxybutynin ext-rel, tolterodine, tolterodine ext-rel, trospium, trospium ext-rel, MYRBETRIQ, TOVIAZ, VESICARE
BENZIQ	adapalene, benzoyl peroxide, clindamycin solution, clindamycin-benzoyl peroxide, erythromycin solution, erythromycin-benzoyl peroxide, tretinoin, ATRALIN, DIFFERIN, EPIDUO, RETIN-A MICRO, TAZORAC	DEXPAK	dexamethasone, methylprednisolone, prednisolone solution, prednisone
BETAPACE, BETAPACE AF	sotalol	DIOVAN, DIOVAN HCT	candesartan, candesartan-hydrochlorothiazide, eprosartan, irbesartan, irbesartan-hydrochlorothiazide, losartan, losartan-hydrochlorothiazide, olmesartan, olmesartan-hydrochlorothiazide, telmisartan, telmisartan-hydrochlorothiazide, valsartan, valsartan-hydrochlorothiazide
BREEZE 2 STRIPS AND KITS 4	ACCU-CHEK AVIVA PLUS STRIPS AND KITS 3, ACCU-CHEK COMPACT PLUS STRIPS AND KITS 3, ACCU-CHEK GUIDE STRIPS AND KITS 3, ACCU-CHEK SMARTVIEW STRIPS AND KITS 3	DORAL	eszopiclone, zolpidem, zolpidem ext-rel, zolpidem sublingual, BELSOMRA, SILENOR
butalbital-acetaminophen-caffeine capsule	diclofenac sodium, naproxen	DORYX	doxycycline hyclate
BYDUREON	OZEMPIC, TRULICITY, VICTOZA	DORYX MPC	doxycycline hyclate
BYETTA	OZEMPIC, TRULICITY, VICTOZA	DULERA	ADVAIR, BREO ELLIPTA, SYMBICORT
		DUTOPROL	metoprolol succinate ext-rel WITH hydrochlorothiazide
		DYRENIUM	amiloride
		EDARBI, EDARBYCLOR	candesartan, candesartan-hydrochlorothiazide, eprosartan, irbesartan, irbesartan-hydrochlorothiazide, losartan, losartan-hydrochlorothiazide, olmesartan, olmesartan-hydrochlorothiazide, telmisartan, telmisartan-hydrochlorothiazide, valsartan, valsartan-hydrochlorothiazide
		EDLUAR	eszopiclone, zolpidem, zolpidem ext-rel, zolpidem sublingual, BELSOMRA, SILENOR
		E.E.S. GRANULES	erythromycins

Your specific prescription benefit plan design may not cover certain products or categories, regardless of their appearance in this document. For specific information, visit [www.caremark.com](http://www.caremark.com) or contact a CVS Caremark Customer Care representative.

**HealthChoice**

DRUG NAME(S)	PREFERRED OPTION(S)*	DRUG NAME(S)	PREFERRED OPTION(S)*
EFFEXOR XR	<i>desvenlafaxine ext-rel, duloxetine, venlafaxine, venlafaxine ext-rel capsule</i>	ISTALOL	<i>timolol maleate solution, BETIMOL</i>
ENABLEX	<i>darifenacin ext-rel, oxybutynin ext-rel, tolterodine, tolterodine ext-rel, trospium, trospium ext-rel, MYRBETRIQ, TOVIAZ, VESICARE</i>	JALYN	<i>dutasteride-tamsulosin; dutasteride or finasteride WITH alfuzosin ext-rel, doxazosin, tamsulosin, terazosin, RAPAFLO</i>
ERYPED	<i>erythromycins</i>	JENTADUETO	JANUMET, JANUMET XR
EVZIO	<i>naloxone injection, NARCAN NASAL SPRAY</i>	JENTADUETO XR	JANUMET, JANUMET XR
EXFORGE	<i>amlodipine-olmesartan, amlodipine-telmisartan, amlodipine-valsartan</i>	KAZANO	JANUMET, JANUMET XR
EXFORGE HCT	<i>amlodipine-valsartan-hydrochlorothiazide, olmesartan-amlodipine-hydrochlorothiazide</i>	KOMBIGLYZE XR	JANUMET, JANUMET XR
FANAPT	<i>aripiprazole, clozapine, olanzapine, quetiapine, quetiapine ext-rel, risperidone, ziprasidone, LATUDA, VRAYLAR</i>	LANOXIN TABLET (125 MCG and 250 MCG only)	<i>digoxin</i>
FEMRING	<i>estradiol, ESTRACE CREAM, ESTRING, PREMARIN CREAM</i>	LANTUS	BASAGLAR, LEVEMIR, TRESIBA
FETZIMA	<i>desvenlafaxine ext-rel, duloxetine, venlafaxine, venlafaxine ext-rel capsule</i>	LAZANDA	<i>fentanyl transmucosal lozenge, ABSTRAL, SUBSYS</i>
FIORICET CAPSULE	<i>diclofenac sodium, naproxen</i>	LESCOL XL	<i>atorvastatin, ezetimibe-simvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin</i>
<i>fluorouracil cream 0.5%</i>	<i>fluorouracil cream 5%, fluorouracil solution, imiquimod, PICATO, TOLAK, ZYCLARA</i>	<i>levorphanol</i>	<i>fentanyl transdermal, hydromorphone ext-rel, methadone, morphine ext-rel, EMBEDA, HYSINGLA ER, NUCYNTA ER, OXYCONTIN</i>
FORTAMET	<i>metformin, metformin ext-rel</i>	LIPITOR	<i>atorvastatin, ezetimibe-simvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin</i>
FORTESTA	<i>testosterone gel, testosterone solution, ANDRODERM, ANDROGEL 1.62%</i>	LIVALO	<i>atorvastatin, ezetimibe-simvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin</i>
FOSAMAX PLUS D	<i>alendronate, ibandronate, risedronate</i>	LUNESTA	<i>eszopiclone, zolpidem, zolpidem ext-rel, zolpidem sublingual, BELSOMRA, SILENOR</i>
FOSRENOL	<i>calcium acetate, lanthanum carbonate, sevelamer carbonate, PHOSLYRA, VELPHORO</i>	MACRODANTIN	<i>nitrofurantoin</i>
FREESTYLE STRIPS AND KITS 4	<i>ACCU-CHEK AVIVA PLUS STRIPS AND KITS 3, ACCU-CHEK COMPACT PLUS STRIPS AND KITS 3, ACCU-CHEK GUIDE STRIPS AND KITS 3, ACCU-CHEK SMARTVIEW STRIPS AND KITS 3</i>	<i>Matzim LA</i>	<i>diltiazem ext-rel (except generic CARDIZEM LA)</i>
FROVA	<i>eletriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan, ONZETRA XSAIL, ZEMBRACE SYMTOUCH, ZOMIG NASAL SPRAY</i>	MENEST	<i>estradiol, estropipate, PREMARIN</i>
GLUMETZA	<i>metformin, metformin ext-rel</i>	MENOSTAR	<i>estradiol</i>
HORIZANT	<i>gabapentin, GRALISE</i>	MIACALCIN INJECTION	<i>alendronate, calcitonin-salmon, ibandronate, risedronate, FORTEO, PROLIA, TYMLOS</i>
HUMALOG	FIASP, NOVOLOG	MIACALCIN NASAL SPRAY	<i>calcitonin-salmon</i>
HUMALOG MIX 50/50	NOVOLOG MIX 70/30	MICARDIS, MICARDIS HCT	<i>candesartan, candesartan-hydrochlorothiazide, eprosartan, irbesartan, irbesartan-hydrochlorothiazide, losartan, losartan-hydrochlorothiazide, olmesartan, olmesartan-hydrochlorothiazide, telmisartan, telmisartan-hydrochlorothiazide, valsartan, valsartan-hydrochlorothiazide</i>
HUMALOG MIX 75/25	NOVOLOG MIX 70/30	MILLIPRED	<i>dexamethasone, methylprednisolone, prednisolone solution, prednisone</i>
HUMULIN 70/30	NOVOLIN 70/30	MINOCIN	<i>minocycline</i>
HUMULIN N	NOVOLIN N	NAPRELAN	<i>diclofenac sodium, meloxicam, naproxen</i>
HUMULIN R	NOVOLIN R	NATESTO	<i>testosterone gel, testosterone solution, ANDRODERM, ANDROGEL 1.62%</i>
INDOCIN	<i>diclofenac sodium, meloxicam, naproxen</i>	NESINA	JANUVIA
INNOPRAN XL	<i>atenolol, carvedilol, metoprolol succinate ext-rel, metoprolol tartrate, nadolol, pindolol, propranolol, propranolol ext-rel, BYSTOLIC, COREG CR</i>	NEXIUM	<i>esomeprazole, lansoprazole, omeprazole, pantoprazole, DEXILANT</i>
INTERMEZZO	<i>eszopiclone, zolpidem, zolpidem ext-rel, zolpidem sublingual, BELSOMRA, SILENOR</i>	NILANDRON	<i>bicalutamide, XTANDI, ZYTIGA</i>
INTUNIV	<i>amphetamine-dextroamphetamine mixed salts ext-rel, atomoxetine, guanfacine ext-rel, methylphenidate ext-rel, MYDAYIS, VYVANSE</i>	NITROMIST	<i>nitroglycerin lingual spray, nitroglycerin sublingual</i>
INVOKAMET	SYNJARDY, SYNJARDY XR, XIGDUO XR	NORITATE	<i>metronidazole, FINACEA, SOOLANTRA</i>
INVOKAMET XR	SYNJARDY, SYNJARDY XR, XIGDUO XR	NORVASC	<i>amlodipine</i>
INVOKANA	FARXIGA, JARDIANCE	NOVACORT	<i>desonide, hydrocortisone</i>
		NOVO NORDISK NEEDLES 5	BD ULTRAFINE NEEDLES
		NUVIGIL	<i>armodafinil</i>
		OLEPTRO	<i>trazodone</i>

Your specific prescription benefit plan design may not cover certain products or categories, regardless of their appearance in this document. For specific information, visit [www.caremark.com](http://www.caremark.com) or contact a CVS Caremark Customer Care representative.

**HealthChoice**

DRUG NAME(S)	PREFERRED OPTION(S)*	DRUG NAME(S)	PREFERRED OPTION(S)*
OLUX-E	<i>clobetasol foam</i>	RIOMET	<i>metformin, metformin ext-rel</i>
OMNARIS	<i>flunisolide, fluticasone, mometasone, triamcinolone, DYMISTA</i>	ROZEREM	<i>eszopiclone, zolpidem, zolpidem ext-rel, zolpidem sublingual, BELSOMRA, SILENOR</i>
ONETOUCH ULTRA STRIPS AND KITS 4	ACCU-CHEK AVIVA PLUS STRIPS AND KITS 3, ACCU-CHEK COMPACT PLUS STRIPS AND KITS 3, ACCU-CHEK GUIDE STRIPS AND KITS 3, ACCU-CHEK SMARTVIEW STRIPS AND KITS 3	SEROQUEL XR	<i>aripiprazole, clozapine, olanzapine, quetiapine, quetiapine ext-rel, risperidone, ziprasidone, LATUDA, VRAYLAR</i>
ONETOUCH VERIO STRIPS AND KITS 4	ACCU-CHEK AVIVA PLUS STRIPS AND KITS 3, ACCU-CHEK COMPACT PLUS STRIPS AND KITS 3, ACCU-CHEK GUIDE STRIPS AND KITS 3, ACCU-CHEK SMARTVIEW STRIPS AND KITS 3	SORILUX	<i>calcipotriene</i>
ONEXTON	<i>adapalene, benzoyl peroxide, clindamycin solution, clindamycin-benzoyl peroxide, erythromycin solution, erythromycin-benzoyl peroxide, tretinoin, ATRALIN, DIFFERIN, EPIDUO, RETIN-A MICRO, TAZORAC</i>	SPRIX	<i>diclofenac sodium, meloxicam, naproxen</i>
ONGLYZA	JANUVIA	STRIANT	<i>testosterone gel, testosterone solution, ANDRODERM, ANDROGEL 1.62%</i>
OSENI	JANUMET, JANUMET XR	SURE-TEST STRIPS AND KITS 4	ACCU-CHEK AVIVA PLUS STRIPS AND KITS 3, ACCU-CHEK COMPACT PLUS STRIPS AND KITS 3, ACCU-CHEK GUIDE STRIPS AND KITS 3, ACCU-CHEK SMARTVIEW STRIPS AND KITS 3
OWEN MUMFORD NEEDLES 5	BD ULTRAFINE NEEDLES	SYNERDERM	<i>desonide, hydrocortisone</i>
OXYTROL	<i>darifenacin ext-rel, oxybutynin ext-rel, tolterodine, tolterodine ext-rel, trospium, trospium ext-rel, MYRBETRIQ, TOVIAZ, VESICARE</i>	TANZEUM	OZEMPIC, TRULICITY, VICTOZA
PANCREAZE	CREON, VIOKACE, ZENPEP	TARGADOX	<i>doxycycline hyclate</i>
PENNSAID	<i>diclofenac sodium, diclofenac sodium gel 1%, diclofenac sodium solution, meloxicam, naproxen</i>	TESTIM	<i>testosterone gel, testosterone solution, ANDRODERM, ANDROGEL 1.62%</i>
PERRIGO NEEDLES 5	BD ULTRAFINE NEEDLES	<i>testosterone gel 1% 6</i>	<i>testosterone gel, testosterone solution, ANDRODERM, ANDROGEL 1.62%</i>
PERTZYE	CREON, VIOKACE, ZENPEP	TIROSINT	<i>levothyroxine, SYNTHROID</i>
PEXEVA	<i>citalopram, escitalopram, fluoxetine, paroxetine HCl, paroxetine HCl ext-rel, sertraline, TRINTELLX, VIIBRYD</i>	TOUJEO	BASAGLAR, LEVEMIR, TRESIBA
PLAVIX	<i>clopidogrel, prasugrel, BRILINTA</i>	TRADJENTA	JANUVIA
PRADAXA	<i>warfarin, ELIQUIS, XARELTO</i>	TRICOR	<i>fenofibrate, fenofibric acid</i>
PRECISION XTRA STRIPS AND KITS 4	ACCU-CHEK AVIVA PLUS STRIPS AND KITS 3, ACCU-CHEK COMPACT PLUS STRIPS AND KITS 3, ACCU-CHEK GUIDE STRIPS AND KITS 3, ACCU-CHEK SMARTVIEW STRIPS AND KITS 3	TRIGLIDE	<i>fenofibrate, fenofibric acid</i>
PRED FORTE	<i>dexamethasone, prednisolone acetate 1%, DUREZOL, FLAREX, FML FORTE, FML S.O.P., MAXIDEX, PRED MILD</i>	TRILIPIX	<i>fenofibrate, fenofibric acid</i>
PREFERAOB	<i>generic prenatal vitamins, CITRANATAL</i>	TRIVIDIA INSULIN SYRINGES 5	BD ULTRAFINE INSULIN SYRINGES
PREFEST	<i>estradiol-norethindrone, PREMPHASE, PREMPRO</i>	TRUETEST STRIPS AND KITS 4	ACCU-CHEK AVIVA PLUS STRIPS AND KITS 3, ACCU-CHEK COMPACT PLUS STRIPS AND KITS 3, ACCU-CHEK GUIDE STRIPS AND KITS 3, ACCU-CHEK SMARTVIEW STRIPS AND KITS 3
PRENATAL PLUS	<i>generic prenatal vitamins, CITRANATAL</i>	TUDORZA	INCRUSE ELLIPTA, SPIRIVA
PREVACID	<i>esomeprazole, lansoprazole, omeprazole, pantoprazole, DEXILANT</i>	ULTIMED INSULIN SYRINGES 5	BD ULTRAFINE INSULIN SYRINGES
PRIMLEV	<i>hydrocodone-acetaminophen, hydromorphone, morphine, oxycodone-acetaminophen, NUCYNTA</i>	ULTIMED NEEDLES 5	BD ULTRAFINE NEEDLES
PROTONIX	<i>esomeprazole, lansoprazole, omeprazole, pantoprazole, DEXILANT</i>	UROXATRAL	<i>alfuzosin ext-rel, doxazosin, tamsulosin, terazosin, RAPAFLO</i>
PROTOPIC	<i>tacrolimus, ELIDEL, EUCRISA</i>	VALCYTE	<i>valganciclovir</i>
PROVENTIL HFA	<i>levalbuterol tartrate CFC-free aerosol, PROAIR HFA, PROAIR RESPICLICK</i>	VALTREX	<i>acyclovir, valacyclovir</i>
QNASL	<i>flunisolide, fluticasone, mometasone, triamcinolone, DYMISTA</i>	VANATOL LQ	<i>diclofenac sodium, naproxen</i>
RAYOS	<i>dexamethasone, methylprednisolone, prednisolone solution, prednisone</i>	VANATOL S	<i>diclofenac sodium, naproxen</i>
RELION INSULIN	NOVOLIN INSULIN	<i>Vanoxide-HC</i>	<i>adapalene, benzoyl peroxide, clindamycin solution, clindamycin-benzoyl peroxide, erythromycin solution, erythromycin-benzoyl peroxide, tretinoin, ATRALIN, DIFFERIN, EPIDUO, RETIN-A MICRO, TAZORAC</i>
RELISTOR	MOVANTIK	VELTIN	<i>adapalene, benzoyl peroxide, clindamycin solution, clindamycin-benzoyl peroxide, erythromycin solution, erythromycin-benzoyl peroxide, tretinoin, ATRALIN, DIFFERIN, EPIDUO, RETIN-A MICRO, TAZORAC</i>
RIMSO-50	Consult doctor	<i>venlafaxine ext-rel tablet (except 225 mg)</i>	<i>desvenlafaxine ext-rel, duloxetine, venlafaxine, venlafaxine ext-rel capsule</i>

Your specific prescription benefit plan design may not cover certain products or categories, regardless of their appearance in this document. For specific information, visit [www.caremark.com](http://www.caremark.com) or contact a CVS Caremark Customer Care representative.

**HealthChoice**

DRUG NAME(S)	PREFERRED OPTION(S)*	DRUG NAME(S)	PREFERRED OPTION(S)*
VENLAFAXINE EXT-REL TABLET (except 225 MG)	<i>desvenlafaxine ext-rel, duloxetine, venlafaxine, venlafaxine ext-rel capsule</i>	ZIANA	<i>adapalene, benzoyl peroxide, clindamycin solution, clindamycin-benzoyl peroxide, erythromycin solution, erythromycin-benzoyl peroxide, tretinoin, ATRALIN, DIFFERIN, EPIDUO, RETIN-A MICRO, TAZORAC</i>
VENTOLIN HFA	<i>levalbuterol tartrate CFC-free aerosol, PROAIR HFA, PROAIR RESPICLICK</i>	ZOLPIMIST	<i>eszopiclone, zolpidem, zolpidem ext-rel, zolpidem sublingual, BELSOMRA, SILENOR</i>
VITAFOL-ONE	<i>generic prenatal vitamins, CITRANATAL</i>	ZONEGRAN	<i>carbamazepine, carbamazepine ext-rel, divalproex sodium, divalproex sodium ext-rel, gabapentin, lamotrigine, lamotrigine ext-rel, levetiracetam, levetiracetam ext-rel, oxcarbazepine, phenobarbital, phenytoin, phenytoin sodium extended, tiagabine, topiramate, valproic acid, zonisamide, FYCOMPA, OXTELLAR XR, TROKENDI XR, VIMPAT</i>
VOGELXO	<i>testosterone gel, testosterone solution, ANDRODERM, ANDROGEL 1.62%</i>	ZUPLENZ	<i>granisetron, ondansetron, SANCUSO</i>
XOPENEX HFA	<i>levalbuterol tartrate CFC-free aerosol, PROAIR HFA, PROAIR RESPICLICK</i>	ZYFLO, ZYFLO CR	<i>montelukast, zafirlukast, zileuton ext-rel</i>
ZEGERID	<i>esomeprazole, lansoprazole, omeprazole, pantoprazole, DEXILANT</i>		
ZETIA	<i>ezetimibe</i>		
ZETONNA	<i>flunisolide, fluticasone, mometasone, triamcinolone, DYMISTA</i>		

You may be responsible for the full cost of certain non-formulary products that are removed from coverage. Please check with your plan sponsor for more information.

**FOR YOUR INFORMATION:** Generics should be considered the first line of prescribing. This drug list represents a summary of prescription coverage. It is not all-inclusive and does not guarantee coverage. New-to-market products and new variations of products already in the marketplace will not be added to the formulary immediately. Each product will be evaluated for clinical appropriateness and cost-effectiveness. Recommended additions to the formulary will be presented to the CVS Caremark National Pharmacy and Therapeutics Committee (or other appropriate reviewing body) for review and approval. In most instances, a brand-name drug for which a generic product becomes available will be designated as a non-preferred option upon release of the generic product to the market. Specific prescription benefit plan design may not cover certain products or categories, regardless of their appearance in this document. The member's prescription benefit plan may have a different copay<sup>1</sup> for specific products on the list. Unless specifically indicated, drug list products will include all dosage forms. This list represents brand products in CAPS, branded generics in upper- and lowercase *italics*, and generic products in lowercase *italics*. Generics listed in therapeutic categories are for representational purposes only. Listed products may be available generically in certain strengths or dosage forms. Dosage forms on this list will be consistent with the category and use where listed. Log in to [www.caremark.com](http://www.caremark.com) to check coverage and copay<sup>1</sup> information for a specific medicine.

An exception process may exist for specific clinical or regulatory circumstances that may require coverage of an excluded medication.

\* The preferred options in this list are a broad representation within therapeutic categories of available treatment options and do not necessarily represent clinical equivalency.

§ Generics are available in this class and should be considered the first line of prescribing.

<sup>1</sup> Copayment, copay or coinsurance means the amount a member is required to pay for a prescription in accordance with a Plan, which may be a deductible, a percentage of the prescription price, a fixed amount or other charge, with the balance, if any, paid by a Plan.

<sup>2</sup> Listing does not include generic CARDIZEM LA.

<sup>3</sup> An ACCU-CHEK blood glucose meter may be provided at no charge by the manufacturer to those individuals currently using a meter other than ACCU-CHEK. For more information on how to obtain a blood glucose meter, call: 1-877-418-4746.

<sup>4</sup> ACCU-CHEK brand test strips are the only preferred options.

<sup>5</sup> BD ULTRAFINE syringes and needles are the only preferred options.

<sup>6</sup> Listing reflects the authorized generics for TESTIM and VOGELXO.

Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers. Listed products are for informational purposes only and are not intended to replace the clinical judgment of the prescriber. The document is subject to state-specific regulations and rules, including, but not limited to, those regarding generic substitution, controlled substance schedules, preference for brands and mandatory generics whenever applicable.

The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2018. All rights reserved. 106-1063953-1-010119

[www.caremark.com](http://www.caremark.com)

Your specific prescription benefit plan design may not cover certain products or categories, regardless of their appearance in this document. For specific information, visit [www.caremark.com](http://www.caremark.com) or contact a CVS Caremark Customer Care representative.

**HealthChoice**

**EXHIBIT C**  
**FILED UNDER SEAL**